Pseudopseudohypoparathyroidism

Genetic MONDO:0012912 Pathograph 26 Show in embeddings browser Disorder of GNAS Inactivation Acromelic Dysplasia

Pseudopseudohypoparathyroidism (PPHP) is a GNAS-related disorder in which patients have Albright hereditary osteodystrophy features, such as brachydactyly, short stature, rounded face, and ectopic ossification, but classically lack parathyroid hormone resistance.

Ask OpenScientist

Ask a research question about Pseudopseudohypoparathyroidism. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

10
Pathophys.
13
Phenotypes
2
Hypotheses
1
Gaps
26
Pathograph
1
Genes
5
Medical Actions
5
Differentials
4
Trials
6
Models
2
References
1
Deep Research
2
Hyp. Reports
◈

Mechanistic Hypotheses

2
Paternal GNAS Loss-of-Function Model
pphp_parent_of_origin_model CANONICAL
Evidence balance 7 support
A paternal GNAS coding loss-of-function variant reduces Gs-alpha dosage in biallelic tissues, producing AHO skeletal and soft-tissue features while usually sparing classic renal PTH resistance because of pre-existing tissue-specific imprinting.
Canonical after review of the OpenScientist synthesis. Renal imprinting context is distinct from the PPHP mutation-driven causal path; STX16 imprinting-establishment experiments concern PHP1B. Human thyroid imprinting is incomplete and fetal bulk renal cortex can show biallelic expression, so mouse tissue results cannot be made universal across human cells and ages. Rare paternal-variant hormone-resistance cases exist. Severe early obesity is typically maternal-variant associated, but universal PPHP leanness is not established. Shared-exon XL-alpha-s effects are variant-dependent modifiers, and PPHP, POH and osteoma cutis remain distinguishable phenotypes.
Deep research
OpenScientist citations 30 citations 2026-05-23T03:37:09.231913
Show evidence (7 references)
PMID:9671744 SUPPORT Model Organism
"Gsalpha expression in the renal cortex (the site of PTH action) is markedly reduced in m-/+ but not in +/p- mice"
Maternal versus paternal disruption demonstrates the renal parent-of-origin effect in mice.
PMID:16099856 SUPPORT Model Organism
"Heterozygous mice that inherited the disruption maternally (-m/+) exhibited PTH and TSH resistance, whereas those with paternal inheritance (+/-p) had normal hormone responsiveness"
Exon-1-specific disruption separates Gs-alpha from effects on other GNAS transcripts.
PMID:15459318 SUPPORT Model Organism
"Gsalpha mRNA expression detected by real-time RT-PCR analysis was reduced to approximately half that of the wild-type in both paternal and maternal Gnas(+/E2-) growth plate chondrocytes, indicating biallelic expression of Gsalpha in these cells."
Approximately half-normal RNA after either parental disruption supports biallelic growth-plate dosage.
+ 4 more references
AHO Developmental Tissue Model
aho_developmental_model CANONICAL
Evidence balance 9 support
Reduced Gs-alpha signaling disrupts growth-plate maturation and mesenchymal osteogenic programs. Separate growth and ectopic-ossification pathways explain core AHO skeletal features, while selective digit involvement and human lesion-cell mechanisms remain incompletely resolved.
Canonical core with qualified experimental branches after OpenScientist assessment. Heterozygous chimera evidence is distinguished from complete conditional knockouts. Mouse dermal-sheath lineage tracing is not human lineage proof. Hedgehog, YAP-SHH and microenvironment studies in POH models add mechanisms beyond a simple adipogenic-to-osteogenic switch. The 2025 study includes a small mixed PPHP/PHP1A/POH fibroblast microarray, contrary to the report omics-absence claim. SFRP2 deletion worsens ossification in male AHO mice, indicating a protective modifier; recombinant SFRP2 did not rescue explants. Somatic second hits remain hypothetical. No established PPHP skeletal disease-modifying therapy follows from these studies.
Deep research
OpenScientist citations 29 citations 2026-05-23T04:46:10.255386
Show evidence (9 references)
PMID:15459318 SUPPORT Model Organism
"Gsalpha mRNA expression detected by real-time RT-PCR analysis was reduced to approximately half that of the wild-type in both paternal and maternal Gnas(+/E2-) growth plate chondrocytes, indicating biallelic expression of Gsalpha in these cells."
Approximately half-normal RNA after either parental disruption supports biallelic growth-plate dosage.
PMID:15459318 SUPPORT Model Organism
"Hypertrophy of Gnas(+/E2-) chondrocytes was modestly but significantly premature in chimeric growth plates of mice containing wild-type and Gnas(+/E2-) cells."
The heterozygous chimera shows modest premature hypertrophy; it does not establish human digit selectivity.
PMID:15765186 SUPPORT Model Organism
"Mice with complete chondrocyte-specific G(s)alpha deficiency (homozygotes) died within minutes after birth and had severe epiphyseal and growth plate defects with shortening of the proliferative zone and accelerated hypertrophic differentiation of growth plate chondrocytes, a phenotype similar..."
Complete conditional knockout establishes pathway necessity, whereas heterozygotes in this separate model had no overt phenotype.
+ 6 more references
?

Discussions and Knowledge Gaps

1
Should GNAS missense variants with mixed receptor-specific gain- and loss-of-function behaviour be curated inside the PPHP parent-of-origin model, or as a separate entity?
OPEN QUESTION OPEN gnas_mixed_function_variant_scope
Attached to
mechanistic_hypotheses#pphp_parent_of_origin_model genetic#GNAS
A small number of germline GNAS missense variants act as constitutive, ligand-independent activators at one receptor while blunting ligand-dependent signaling at another. Carriers present with nephrogenic syndrome of inappropriate antidiuresis, precocious puberty, or osteolytic metaphyseal bone disease rather than with AHO, and at least two reported variants sat on the paternal allele. These are not counterexamples to the parent-of-origin model, which is stated for coding loss-of-function variants, but they do mean a paternal GNAS missense finding cannot be assumed loss-of-function from its position alone. The practical question for this entry is whether the scope sentence already carried in the genetic notes is enough, or whether the mixed-function phenotypes need their own entry; the frequency of such variants among GNAS missense findings has never been measured, which is what makes the question hard to settle.
Show evidence (3 references)
PMID:30312418 SUPPORT In Vitro
"In vitro studies demonstrated that Gαs-F376V enhanced ligand-independent signaling at the PTH1R, LHCGR, and V2R and, at the same time, blunted ligand-dependent responses."
The original demonstration that one GNAS missense variant can be activating and inactivating at once, depending on receptor and on whether ligand is present. This variant was maternal, so it establishes the phenomenon rather than the paternal-allele case.
PMID:40172207 SUPPORT Human Clinical
"One of the mothers, with the variant in her paternal allele, presented NSIAD."
Places a mixed-function variant on the paternal allele in a carrier who presented with inappropriate antidiuresis rather than with AHO, which is the observation that makes this a scope question for the PPHP model.
PMID:41530545 SUPPORT In Vitro
"Luciferase assays for p.Thr55Ala showed ligand-independent GOF effects on AVPR2 and PTH1R signalings, and a ligand-dependent loss-of-function (LOF) effect on PTH1R signaling."
A second variant with the same dual behaviour, assayed receptor by receptor. It arose de novo on the paternally inherited allele in a patient with inappropriate antidiuresis and osteolytic metaphyseal bone disease rather than AHO, which is the genotype-to-allele combination a paternal-variant model would otherwise be read as predicting.
⚙

Pathophysiology

10
Paternal GNAS coding loss of function
A heterozygous inactivating GNAS coding variant on the paternal chromosome causes the classical PPHP phenotype. It can be inherited or de novo. Pre-existing tissue-specific imprinting usually preserves sufficient maternal renal Gs-alpha signaling; the variant does not itself create normal imprinting or an STX16 deletion.
GNAS hgnc:4392 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves GNAS (hgnc:4392). hgnc:4392 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
Reduced Gs-alpha dosage in biallelic tissues Loss of one expressed Gs-alpha allele reduces dosage in biallelic skeletal and mesenchymal contexts.
Reduced XL-alpha-s function in shared-exon variants Variants involving shared exons can additionally impair the paternally expressed XL-alpha-s isoform; functional consequences depend on the variant.
Show evidence (1 reference)
PMID:15711092 SUPPORT Other
"PHP-Ia and PPHP are caused by heterozygous inactivating mutations in those exons of GNAS encoding the alpha subunit of the stimulatory guanine nucleotide-binding protein (Gsalpha)"
This supports heterozygous inactivating GNAS coding variants as causal for PPHP.
Reduced Gs-alpha dosage in biallelic tissues
Reduced Gs-alpha dosage impairs receptor coupling to adenylyl cyclase and cAMP signaling. Biallelic expression is demonstrated in mouse growth-plate chondrocytes; tissue, developmental stage and parent of origin can still modify downstream responses.
cAMP/PKA signal transduction GO:0141156 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves cAMP/PKA signal transduction (GO:0141156). GO:0141156 is a biological process from the Gene Ontology.
Animal models
Parent-specific heterozygous Gnas exon-1 mouse Mouse partially recapitulates Exon-1 heterozygosity models partial Gs-alpha loss; expression studies identify biallelic tissues.
Downstream
Reduced PTHrP-dependent chondrocyte signaling Reduced Gs-alpha weakens the PTHrP receptor signal that restrains chondrocyte maturation.
Mesenchymal osteogenic differentiation bias Reduced cAMP shifts mesenchymal differentiation toward osteogenic programs in experimental systems.
Hedgehog-dependent osteogenic activation Gnas inactivation releases restraint of Hedgehog osteogenic signaling in POH models.
YAP-SHH paracrine recruitment Gnas loss activates YAP-dependent SHH production in related POH models.
Show evidence (1 reference)
PMID:15459318 SUPPORT Model Organism
"Gsalpha mRNA expression detected by real-time RT-PCR analysis was reduced to approximately half that of the wild-type in both paternal and maternal Gnas(+/E2-) growth plate chondrocytes, indicating biallelic expression of Gsalpha in these cells."
Approximately half-normal RNA after either parental disruption supports biallelic growth-plate dosage.
Reduced PTHrP-dependent chondrocyte signaling
Reduced PTHrP/Gs-alpha/cAMP/PKA signaling removes a restraint on growth-plate chondrocyte differentiation. Complete knockout is much more severe than PPHP; dosage-relevant support comes from heterozygous chimeras.
chondrocyte CL:0000138 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves chondrocyte (CL:0000138). CL:0000138 is a cell type from the Cell Ontology.
cAMP/PKA signal transduction GO:0141156 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves cAMP/PKA signal transduction (GO:0141156). GO:0141156 is a biological process from the Gene Ontology.
Animal models
Complete and partial chondrocyte-specific Gnas deletion Mouse perturbs Complete deletion perturbs the PTHrP/Gs-alpha pathway.
Downstream
Premature chondrocyte hypertrophy Reduced receptor signaling advances the transition into hypertrophy.
Show evidence (2 references)
PMID:15459318 SUPPORT Model Organism
"Hypertrophy of Gnas(+/E2-) chondrocytes was modestly but significantly premature in chimeric growth plates of mice containing wild-type and Gnas(+/E2-) cells."
The heterozygous chimera shows modest premature hypertrophy; it does not establish human digit selectivity.
PMID:15765186 SUPPORT Model Organism
"Mice with complete chondrocyte-specific G(s)alpha deficiency (homozygotes) died within minutes after birth and had severe epiphyseal and growth plate defects with shortening of the proliferative zone and accelerated hypertrophic differentiation of growth plate chondrocytes, a phenotype similar..."
Complete conditional knockout establishes pathway necessity, whereas heterozygotes in this separate model had no overt phenotype.
Premature chondrocyte hypertrophy
Heterozygous chimeric chondrocytes undergo modestly premature hypertrophy. Complete chondrocyte deletion shortens the proliferative zone and causes perinatal lethality, which must not be equated with heterozygous human disease.
hypertrophic chondrocyte CL:0000743 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves hypertrophic chondrocyte (CL:0000743). CL:0000743 is a cell type from the Cell Ontology.
Animal models
Heterozygous chondrocyte chimera Mouse partially recapitulates A dosage-relevant cellular phenotype supports the growth-plate mechanism.
Complete and partial chondrocyte-specific Gnas deletion Mouse fails to recapitulate Partial deletion in this model does not reproduce the overt skeletal phenotype.
Downstream
Impaired longitudinal skeletal growth Accelerated maturation can shorten the period of longitudinal growth; the precise human digit-selective mechanism remains unresolved.
Show evidence (2 references)
PMID:15459318 SUPPORT Model Organism
"Hypertrophy of Gnas(+/E2-) chondrocytes was modestly but significantly premature in chimeric growth plates of mice containing wild-type and Gnas(+/E2-) cells."
The heterozygous chimera shows modest premature hypertrophy; it does not establish human digit selectivity.
PMID:15765186 SUPPORT Model Organism
"Mice with complete chondrocyte-specific G(s)alpha deficiency (homozygotes) died within minutes after birth and had severe epiphyseal and growth plate defects with shortening of the proliferative zone and accelerated hypertrophic differentiation of growth plate chondrocytes, a phenotype similar..."
Complete conditional knockout establishes pathway necessity, whereas heterozygotes in this separate model had no overt phenotype.
Impaired longitudinal skeletal growth
Mechanism confidence: Provisional
Premature growth-plate maturation contributes to shortened metacarpals, metatarsals and adult stature. The preference for particular digits is not explained by current mouse experiments, and short stature can also reflect prenatal growth restriction or uncommon endocrine abnormalities.
endochondral bone growth GO:0003416 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves endochondral bone growth (GO:0003416). GO:0003416 is a biological process from the Gene Ontology.
Downstream
Brachydactyly Reduced growth of selected tubular bones produces brachydactyly; regional susceptibility remains incompletely explained.
Short stature Reduced longitudinal growth contributes to adult short stature.
Show evidence (2 references)
PMID:15459318 SUPPORT Model Organism
"Hypertrophy of Gnas(+/E2-) chondrocytes was modestly but significantly premature in chimeric growth plates of mice containing wild-type and Gnas(+/E2-) cells."
The heterozygous chimera shows modest premature hypertrophy; it does not establish human digit selectivity.
PMID:15765186 SUPPORT Model Organism
"Mice with complete chondrocyte-specific G(s)alpha deficiency (homozygotes) died within minutes after birth and had severe epiphyseal and growth plate defects with shortening of the proliferative zone and accelerated hypertrophic differentiation of growth plate chondrocytes, a phenotype similar..."
Complete conditional knockout establishes pathway necessity, whereas heterozygotes in this separate model had no overt phenotype.
Mesenchymal osteogenic differentiation bias
Mechanism confidence: Provisional
Paternal-mutant mouse adipose stromal cells have reduced adipogenic differentiation and increased osteogenic markers, with forskolin rescue of adipogenesis. This is a progenitor fate bias, not proof that mature adipocytes become bone or that every PPHP patient is lean.
mesenchymal stem cell CL:0000134 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves mesenchymal stem cell (CL:0000134). CL:0000134 is a cell type from the Cell Ontology.
osteoblast differentiation GO:0001649 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves osteoblast differentiation (GO:0001649). GO:0001649 is a biological process from the Gene Ontology.
Downstream
Dermal and subcutaneous ectopic bone formation Osteogenic progenitor differentiation contributes to ectopic bone formation, with additional local signaling and tissue-environment effects.
Show evidence (1 reference)
PMID:22511293 SUPPORT Model Organism
"Msh homeobox 2, an early osteogenic marker, runt-related transcription factor 2, an osteogenic transcription factor, and osteocalcin, a marker of terminal osteogenic differentiation were all expressed at higher levels in Gsα+/p− ASCs during adipogenic induction compared to WT ASCs (Fig. 5)."
Paternal-mutant mouse stromal cells express more osteogenic markers even under adipogenic induction. Neither genotype mineralized under those culture conditions, so this demonstrates a differentiation bias rather than completed ectopic bone formation.
Hedgehog-dependent osteogenic activation
Mechanism confidence: Provisional
Gnas-loss models activate Hedgehog-dependent osteogenesis. Human POH lesions show pathway upregulation, but the necessity and extent of this mechanism in heterozygous superficial PPHP lesions are unproven.
mesenchymal stem cell CL:0000134 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves mesenchymal stem cell (CL:0000134). CL:0000134 is a cell type from the Cell Ontology.
osteoblast differentiation GO:0001649 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves osteoblast differentiation (GO:0001649). GO:0001649 is a biological process from the Gene Ontology.
Animal models
Conditional Gnas-null POH models Mouse partially recapitulates Hedgehog perturbation affects ectopic osteogenesis.
Downstream
Dermal and subcutaneous ectopic bone formation Hedgehog pathway activation promotes ectopic osteoblast differentiation in POH models.
Show evidence (2 references)
PMID:24076664 SUPPORT Model Organism
"Here we demonstrate that Gαs restricts bone formation to the skeleton by inhibiting Hedgehog signaling in mesenchymal progenitor cells."
Perturbation studies support a Hedgehog-dependent mechanism in Gnas-null POH models; direct transfer to heterozygous human PPHP remains provisional.
PMID:24076664 SUPPORT Human Clinical
"In progressive osseous heteroplasia, a human disease caused by null mutations in GNAS, which encodes Gαs, Hedgehog signaling is upregulated in ectopic osteoblasts and progenitor cells."
Human lesion evidence is from POH, a related but distinct GNAS ossification disorder.
YAP-SHH paracrine recruitment
Mechanism confidence: Provisional
A YAP-SHH feedback circuit in Gnas-null mesenchymal cells recruits neighboring wild-type cells into osteogenesis. Transplantation studies also show that the mutant tissue environment affects lesion formation. These are POH-model mechanisms requiring confirmation in PPHP.
Animal models
Conditional Gnas-null POH models Mouse partially recapitulates Cell and host manipulations interrogate paracrine propagation.
Downstream
Dermal and subcutaneous ectopic bone formation Paracrine recruitment and a permissive tissue environment expand heterotopic ossification in related models.
Show evidence (2 references)
PMID:34162750 SUPPORT Model Organism
"We further showed that loss of Gnas led to activation of YAP transcription activity, which directly drove Shh expression."
Gnas-null mesenchymal cells support YAP-SHH-mediated propagation; the model is not equivalent to heterozygous PPHP.
PMID:33574833 SUPPORT Model Organism
"We found that mutant cells in a Gnas-null tissue environment induced a robust HO response while little/no HO was detected in control hosts."
Mutant-host transplantation experiments support a permissive non-cell-autonomous environment in a POH model.
Dermal and subcutaneous ectopic bone formation
True intramembranous bone forms in skin and subcutaneous tissue, independently of the serum calcium-phosphate abnormality of PTH resistance. Alpha-SMA lineage tracing supports a dermal-sheath contribution in AHO mice. Progressive invasion of deep fascia and muscle suggests POH or an overlap phenotype rather than classical superficial PPHP.
osteoblast CL:0000062 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves osteoblast (CL:0000062). CL:0000062 is a cell type from the Cell Ontology.
ossification GO:0001503 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves ossification (GO:0001503). GO:0001503 is a biological process from the Gene Ontology.
Experimental models
Patient-derived dermal fibroblast microarrays PRIMARY CELL CULTURE Expression correlates with lesion burden but does not isolate causal human progenitors.
Animal models
Parent-specific heterozygous Gnas exon-1 mouse Mouse partially recapitulates Both parental forms develop AHO-like ectopic bone.
AHO alpha-SMA lineage tracing and Sfrp2 modifier mouse Mouse partially recapitulates Lineage tracing identifies contributing cells and modifier perturbation changes lesion burden.
Downstream
Ectopic ossification Formation of bone outside the skeleton produces the clinical lesions.
Osteoma cutis Dermal lesions can be classified as osteoma cutis.
Show evidence (3 references)
PMID:21747923 SUPPORT Model Organism
"Gnas(E1-/+) mice develop SCO features that are similar to those observed in AHO patients"
Heterozygous Gnas exon-1 mice reproduce superficial ectopic bone.
PMID:29059381 SUPPORT Human Clinical
"RESULTS: Forty-seven of 67 participants (70.1%) had SCOs. Patients with PHP1A and PPHP had similar prevalences and degrees of ossification formation. Patients with frameshift and nonsense mutations had much more extensive SCOs than those with missense mutations. Males were affected more than..."
The 67-person AHO cohort included 18 PPHP cases; ossification burden was similar between PPHP and PHP1A and did not correlate with BMI or hormone status.
PMID:40256763 SUPPORT Model Organism
"Here we show that SCO formation occurs due to inappropriate expansion and osteogenic differentiation of cells that express alpha-smooth muscle actin and that are located within the dermal sheath."
Mouse alpha-SMA fate mapping supports a dermal-sheath contribution; initial labeling includes additional alpha-SMA populations and does not establish human cell identity.
Reduced XL-alpha-s function in shared-exon variants
Mechanism confidence: Provisional
Shared-exon GNAS variants can affect XL-alpha-s as well as Gs-alpha. Lower birth weight in a mixed PPHP/POH cohort supports a fetal-growth modifier, but isoform-specific effects have not been isolated from mutation class or broader locus effects in patients.
Downstream
Intrauterine growth retardation Reduced XL-alpha-s function is a plausible contributor to prenatal growth restriction; paternal exon-1 variants also lower birth weight.
Show evidence (2 references)
PMID:23884777 SUPPORT Human Clinical
"birth weights were lower with paternal GNAS mutations affecting exons 2-13 than with exon 1/intron 1 mutations."
Birth parameters from 26 PPHP/POH and 29 PHP-Ia patients support an exon-class association, not isolated proof that XL-alpha-s determines fetal growth.
PMID:22215617 SUPPORT Model Organism
"paternal inheritance of Ex1A-T results in an increased metabolic rate and reductions in fat mass, leptin, and bone mineral density attributable to loss of XLαs"
The engineered mouse allele supports isoform-dependent effects but also changes locus dosage; human effects are variant-dependent.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Pseudopseudohypoparathyroidism Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

13
Head and Neck 1
Round face FREQUENT HP:0000311 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Round face (HP:0000311). HP:0000311 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:79445 SUPPORT Other
"HP:0000311 | Round face | Frequent (79-30%)"
Orphanet lists round face as frequent in PPHP.
Integument 1
Osteoma cutis OCCASIONAL HP:0025027 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Osteoma cutis (HP:0025027). HP:0025027 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:79445 SUPPORT Other
"HP:0025027 | Osteoma cutis | Occasional (29-5%)"
Orphanet lists osteoma cutis as occasional in PPHP.
Limbs 5
Brachydactyly FREQUENT HP:0001156 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Brachydactyly (HP:0001156). HP:0001156 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:79445 SUPPORT Other
"HP:0001156 | Brachydactyly | Frequent (79-30%)"
Orphanet lists brachydactyly as frequent in PPHP.
Short 5th finger FREQUENT HP:0009237 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Short 5th finger (HP:0009237). HP:0009237 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:79445 SUPPORT Other
"HP:0009237 | Short 5th finger | Frequent (79-30%)"
Orphanet lists short fifth finger as frequent in PPHP.
Short 4th metacarpal FREQUENT HP:0010044 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Short 4th metacarpal (HP:0010044). HP:0010044 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:79445 SUPPORT Other
"HP:0010044 | Short 4th metacarpal | Frequent (79-30%)"
Orphanet lists short fourth metacarpal as frequent in PPHP.
Short 5th metacarpal FREQUENT HP:0010047 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Short 5th metacarpal (HP:0010047). HP:0010047 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:79445 SUPPORT Other
"HP:0010047 | Short 5th metacarpal | Frequent (79-30%)"
Orphanet lists short fifth metacarpal as frequent in PPHP.
Short metatarsal FREQUENT HP:0010743 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Short metatarsal (HP:0010743). HP:0010743 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:79445 SUPPORT Other
"HP:0010743 | Short metatarsal | Frequent (79-30%)"
Orphanet lists short metatarsal as frequent in PPHP.
Musculoskeletal 1
Ectopic ossification FREQUENT HP:0011986 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ectopic ossification (HP:0011986). HP:0011986 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
ORPHA:79445 SUPPORT Other
"HP:0011986 | Ectopic ossification | Frequent (79-30%)"
Orphanet lists ectopic ossification as frequent in PPHP.
PMID:29059381 SUPPORT Human Clinical
"RESULTS: Forty-seven of 67 participants (70.1%) had SCOs. Patients with PHP1A and PPHP had similar prevalences and degrees of ossification formation. Patients with frameshift and nonsense mutations had much more extensive SCOs than those with missense mutations. Males were affected more than..."
The 67-person AHO cohort included 18 PPHP cases; ossification burden was similar between PPHP and PHP1A and did not correlate with BMI or hormone status.
Nervous System 2
Delayed speech and language development OCCASIONAL HP:0000750 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Delayed speech and language development (HP:0000750). HP:0000750 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:79445 SUPPORT Other
"HP:0000750 | Delayed speech and language development | Occasional (29-5%)"
Orphanet lists delayed speech and language development as occasional in PPHP.
Intellectual disability OCCASIONAL HP:0001249 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intellectual disability (HP:0001249). HP:0001249 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:79445 SUPPORT Other
"HP:0001249 | Intellectual disability | Occasional (29-5%)"
Orphanet lists intellectual disability as occasional in PPHP.
Growth 3
Short stature FREQUENT HP:0004322 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Short stature (HP:0004322). HP:0004322 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:79445 SUPPORT Other
"HP:0004322 | Short stature | Frequent (79-30%)"
Orphanet lists short stature as frequent in PPHP.
Obesity OCCASIONAL HP:0001513 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Obesity (HP:0001513). HP:0001513 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:79445 SUPPORT Other
"HP:0001513 | Obesity | Occasional (29-5%)"
Orphanet lists obesity as occasional in PPHP.
Intrauterine growth retardation OCCASIONAL HP:0001511 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intrauterine growth retardation (HP:0001511). HP:0001511 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
ORPHA:79445 SUPPORT Other
"HP:0001511 | Intrauterine growth retardation | Occasional (29-5%)"
Orphanet lists intrauterine growth retardation as occasional in PPHP.
PMID:23884777 SUPPORT Human Clinical
"birth weights were lower with paternal GNAS mutations affecting exons 2-13 than with exon 1/intron 1 mutations."
Birth parameters from 26 PPHP/POH and 29 PHP-Ia patients support an exon-class association, not isolated proof that XL-alpha-s determines fetal growth.
🧬

Genetic Associations

1
GNAS (Heterozygous GNAS coding loss of function on the paternal chromosome; inherited or de novo)
Gene: GNAS hgnc:4392 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is GNAS (hgnc:4392). hgnc:4392 is a gene from the HUGO Gene Nomenclature Committee.
Autosomal dominant
Show evidence (4 references)
ORPHA:79445 SUPPORT Other
"GNAS | GNAS complex locus | hgnc:4392 | Disease-causing germline mutation(s) (loss of function) in"
Orphanet identifies GNAS loss-of-function germline mutations as disease-causing in PPHP.
PMID:15711092 SUPPORT Other
"PHP-Ia and PPHP are caused by heterozygous inactivating mutations in those exons of GNAS encoding the alpha subunit of the stimulatory guanine nucleotide-binding protein (Gsalpha)"
This supports heterozygous inactivating GNAS coding variants as causal for PPHP.
PMID:25802881 SUPPORT Human Clinical
"Comparing the clinical features to the molecular genetic data, a significantly higher occurrence of subcutaneous calcifications in patients harboring truncating versus missense mutations was demonstrated."
The one reproducible genotype-phenotype correlation reported for this gene: the severity of the coding lesion tracks with ossification burden. The cohort pooled PHP1A and PPHP patients, so the correlation is a property of GNAS variant class rather than of PPHP specifically.
+ 1 more reference
💊

Medical Actions

5
Individualized clinical surveillance with baseline endocrine assessment
Action: clinical assessmentNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is clinical assessment, annotated with Clinical Evaluation (NCIT:C124351). NCIT:C124351 is a clinical intervention from the NCI Thesaurus. Ontology label: Clinical Evaluation NCIT:C124351
Assess growth, weight, puberty, thyroid function, new or enlarging ossifications, mobility, oral health and educational needs according to the phenotype. Establish calcium, phosphate, PTH and vitamin D status at diagnosis. Confirmed paternal GNAS cases do not require the routine serial PTH/calcium/phosphate testing schedule used for PHP1A; reassess when symptoms, abnormal results or uncertainty about parental phase warrant it. Treat documented hormone deficiencies, not the PPHP label alone.
Target Phenotypes: Ectopic ossification HP:0011986 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Ectopic ossification (HP:0011986). HP:0011986 is a phenotype from the Human Phenotype Ontology. Obesity HP:0001513 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Obesity (HP:0001513). HP:0001513 is a phenotype from the Human Phenotype Ontology. Intellectual disability HP:0001249 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Intellectual disability (HP:0001249). HP:0001249 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:29959430 SUPPORT Other
"At diagnosis or before initiation of treatment, we recommend the monitoring of serum levels of PTH, calcium, phosphorus and calcifediol."
Baseline endocrine biochemistry establishes whether the classical PPHP pattern is present.
PMID:29959430 SUPPORT Other
"exception of patients carrying either a GNAS muta- tion on the paternal allele or a PDE4D mutation in whom, apart from at diagnosis, routine assessment is not necessary."
Recommendation 3.2 exempts paternal GNAS cases from routine repeated PTH/calcium/phosphate measurement after baseline. PDF line-break hyphenation is preserved in this exact excerpt.
url:https://www.ncbi.nlm.nih.gov/books/NBK459117/ SUPPORT Other
"New and/or enlarging ectopic ossifications;"
Clinical follow-up includes lesion progression.
Coordinated multidisciplinary supportive management
Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Management is coordinated across pediatric/adult endocrinology, genetics, orthopedics, dentistry, nutrition, and neurodevelopmental services according to the patient's manifestations.
Target Phenotypes: Brachydactyly HP:0001156 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Brachydactyly (HP:0001156). HP:0001156 is a phenotype from the Human Phenotype Ontology. Short stature HP:0004322 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Short stature (HP:0004322). HP:0004322 is a phenotype from the Human Phenotype Ontology. Ectopic ossification HP:0011986 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Ectopic ossification (HP:0011986). HP:0011986 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29959430 SUPPORT Other
"Overall, a coordinated and multidisciplinary approach from infancy through adulthood, including a transition programme, should help us to improve the care of patients affected by these disorders."
Consensus guidance supports multidisciplinary supportive management for PHP-related disorders including PPHP.
Physical and occupational therapy with skin care
Action: Physical therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Physical therapy (NCIT:C15302). NCIT:C15302 is a clinical intervention from the NCI Thesaurus. Ontology label: Physical Therapy NCIT:C15302
Assess fine motor function and mobility, provide appropriate footwear or orthoses when needed, and maintain skin integrity over superficial ossifications. Tailor therapy to pain or functional limitation. Routine serial imaging of asymptomatic lesions is unnecessary; image painful, function-threatening or surgically considered lesions.
Show evidence (2 references)
PMID:29959430 SUPPORT Other
"Physical therapy and meticulous skin care remain the most important conservative approaches to preserve movement and to prevent cutaneous breakdown, respectively251,252."
Consensus recommends physical therapy and skin care for ectopic ossification; the strength of evidence is limited.
PMID:29959430 SUPPORT Other
"Regular imaging of ectopic ossifications is not indicated"
The consensus favors symptom-directed imaging.
Selective excision of symptomatic superficial ossifications
Action: Excision of superficial ossificationsNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Excision of superficial ossifications, annotated with Excision (NCIT:C15232). NCIT:C15232 is a clinical intervention from the NCI Thesaurus. Ontology label: Excision NCIT:C15232
An experienced surgeon may remove localized superficial lesions causing irritation, pain or impaired movement. Recurrence can occur. Deep progressive ossification needs specialist reassessment for POH overlap; surgery does not correct the underlying GNAS defect.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK459117/ SUPPORT Other
"Subcutaneous ossifications that are superficial and well circumscribed may be surgically removed when they are large or cause local irritation, although they may recur."
Surgery is selective and recurrence is possible.
Genetic counselling and family testing
Action: Genetic counsellingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic counselling, annotated with Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. Ontology label: Genetic Counseling NCIT:C15240
Each child of a heterozygous carrier has a 50% chance of inheriting the variant. The sex of the transmitting parent changes the expected phenotype in the child: paternal transmission usually causes PPHP/POH/osteoma cutis, whereas maternal transmission usually causes PHP1A. Establish phase and test relatives as appropriate; discuss variable expression, de novo or mosaic variants, and reproductive testing options.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK459117/ SUPPORT Other
"inactivation has a 50% chance of inheriting the parent's genetic alteration"
GeneReviews supplies transmission risk; phenotype prediction also requires imprinting and parental origin.
🔬

Biochemical Markers

4
Parathyroid hormone resistance (Absent in classical PPHP)
Context: Classical PPHP usually lacks PTH resistance. Rare phased paternal-variant cases with elevated PTH or blunted GH stimulation exist; this is an exception, not the defining biochemical pattern.
Show evidence (3 references)
ORPHA:79445 SUPPORT Other
"but no evidence of resistance to parathyroid hormone (PTH)"
Orphanet defines PPHP by AHO clinical features without evidence of PTH resistance.
PMID:25464124 SUPPORT Human Clinical
"These findings suggest that PTH and other hormone resistance may not be an exclusive feature of PHP-Ia and could also be observed in patients with PPHP."
This case report supports noting that hormone resistance can occasionally complicate the classical PPHP distinction.
PMID:34254228 SUPPORT Human Clinical
"he met the diagnostic criteria for POH, and mild PTH and TSH resistance was detected"
Adds a timing caveat to the biochemical pattern. In this case from the severe end of the GNAS-inactivation spectrum, pituitary stimulation was normal at 3 years and the TSH response was reduced at 13 years, so a normal childhood panel does not settle the question for life. The variant arose de novo and its parental allele was not determined, so the case does not itself demonstrate resistance with a phased paternal variant.
Serum calcium (Normal)
Context: Classical PPHP does not show the hypocalcemia typical of PTH resistance.
Show evidence (1 reference)
ORPHA:79445 SUPPORT Other
"HP:0002901 | Hypocalcemia | Excluded (0%)"
Orphanet explicitly excludes hypocalcemia from the PPHP phenotype.
Serum phosphate (Normal)
Context: Classical PPHP does not show the hyperphosphatemia typical of PTH resistance.
Show evidence (1 reference)
ORPHA:79445 SUPPORT Other
"HP:0002905 | Hyperphosphatemia | Excluded (0%)"
Orphanet explicitly excludes hyperphosphatemia from the PPHP phenotype.
Circulating parathyroid hormone (Not elevated in classical PPHP)
Context: PTH is normally not elevated in classical PPHP. An unexpected elevation requires assessment of calcium, phosphate, vitamin D, renal function and the molecular diagnosis.
Show evidence (1 reference)
ORPHA:79445 SUPPORT Other
"HP:0003165 | Elevated circulating parathyroid hormone level | Excluded (0%)"
Orphanet explicitly excludes elevated circulating PTH from classical PPHP.
🔬

Diagnosis

2
Clinical and biochemical recognition of AHO without PTH resistance
Recognize the evolving AHO pattern using growth history, examination for superficial ossification, and hand/foot radiographs when useful. Obtain baseline calcium, phosphate, PTH, vitamin D and thyroid function to establish the endocrine phenotype and identify mimics. Routine PTH infusion testing is rarely required.
clinical assessment NCIT:C124351 NCI Thesaurus (NCIT)
Results: AHO features with no classical PTH resistance.
Show evidence (3 references)
ORPHA:79445 SUPPORT Other
"Pseudopseudohypoparathyroidism (pseudo-PHP) is a disease characterized by a constellation of clinical features collectively termed Albright hereditary osteodystrophy (AHO) but no evidence of resistance to parathyroid hormone (PTH), which is seen in other forms of pseudohypoparathyroidism (PHP)."
Orphanet defines the diagnostic distinction between PPHP and other PHP forms.
PMID:15711092 SUPPORT Other
"These features are also present in pseudopseudohypoparathyroidism (PPHP), but patients affected by this disorder do not show hormone resistance."
This review supports assessing AHO features together with absent hormone resistance.
PMID:29959430 SUPPORT Other
"At diagnosis or before initiation of treatment, we recommend the monitoring of serum levels of PTH, calcium, phosphorus and calcifediol."
Baseline endocrine biochemistry establishes whether the classical PPHP pattern is present.
GNAS molecular genetic testing
Sequence GNAS coding exons and splice junctions and assess deletion/duplication when sequencing is unrevealing. Determine parental phase by family testing or informative molecular markers; a de novo variant may still be paternal. Methylation and imprinting-control testing are particularly relevant when the phenotype suggests PHP1B or coding testing is negative; an STX16 defect is not the usual cause of PPHP.
molecular genetic testing NCIT:C19770 NCI Thesaurus (NCIT)
Results: Heterozygous GNAS loss-of-function variant, classically on the paternal allele.
Show evidence (3 references)
PMID:29959430 SUPPORT Other
"The clinical and laboratory diagnosis should be confirmed by a molecular genetic analysis."
Consensus guidance supports molecular genetic analysis to confirm PHP-related disorder diagnosis.
ORPHA:79445 SUPPORT Other
"GNAS | GNAS complex locus | hgnc:4392 | Disease-causing germline mutation(s) (loss of function) in"
Orphanet identifies GNAS loss-of-function variants as the causal molecular finding.
url:https://www.ncbi.nlm.nih.gov/books/NBK459117/ SUPPORT Other
"Sequence analysis of exons 1 through 13 of"
The testing sequence includes copy-number analysis rather than coding sequencing alone.
📈

Progression

2
Prenatal and childhood growth abnormalities
Intrauterine growth restriction can precede recognizable AHO. Brachydactyly and short stature evolve with skeletal maturation rather than necessarily being complete at birth.
Show evidence (1 reference)
PMID:23884777 SUPPORT Human Clinical
"Heterozygous GNAS mutations on either parental allele were associated with IUGR."
The birth-parameter cohort documents prenatal involvement.
Variable lifelong superficial ossification burden
Superficial ossification burden can increase with age, with substantial variability within and between families. Deep progressive extension indicates a POH or overlap phenotype and is not an obligatory PPHP trajectory.
Show evidence (1 reference)
PMID:29059381 SUPPORT Human Clinical
"Males are affected more extensively than females, and the SCOs tend to worsen with age."
Longitudinal clinical assessment supports age-related lesion burden.
📊

Prevalence

1
Europe point prevalence
Point Prevalence Unknown Unknown
Show evidence (1 reference)
ORPHA:79445 SUPPORT Other
"Unknown | Europe | Point prevalence | ORPHANET"
Orphanet reports unknown point prevalence for PPHP in Europe.
🔀

Differential Diagnoses

5

Conditions with similar clinical presentations that must be differentiated from Pseudopseudohypoparathyroidism:

Pseudohypoparathyroidism type 1A
Overlapping Features Maternal coding GNAS variants can produce the same AHO skeletal findings.
Distinguishing Features
  • PTH and other hormone resistance and severe early-onset obesity favor PHP1A; parental phase is decisive when findings overlap.
Show evidence (1 reference)
PMID:16099856 SUPPORT Model Organism
"Heterozygous mice that inherited the disruption maternally (-m/+) exhibited PTH and TSH resistance, whereas those with paternal inheritance (+/-p) had normal hormone responsiveness"
The exon-1 model supports the biological basis of the clinical distinction.
Progressive osseous heteroplasia
Overlapping Features POH can result from paternal GNAS inactivation and share superficial ossifications with PPHP.
Distinguishing Features
  • Progressive extension into deep fascia and skeletal muscle, often without the full AHO pattern, distinguishes POH. Overlap phenotypes occur, so it is not a predictable PPHP stage.
Show evidence (1 reference)
PMID:33574833 SUPPORT Model Organism
"HO typically initiates within subcutaneous soft tissues before progressing to deeper connective tissues."
The primary POH study defines the progressive lesion phenotype; it is not evidence that all PPHP progresses deeply.
Acrodysostosis due to PRKAR1A or PDE4D
Overlapping Features Other cAMP/PKA-pathway disorders cause overlapping short stature and brachydactyly.
Distinguishing Features
  • Diffuse early brachydactyly, nasal hypoplasia and advanced bone age suggest acrodysostosis; hormone resistance varies by genotype. PRKAR1A is iPPSD4 and PDE4D is iPPSD5.
Show evidence (3 references)
url:https://www.ncbi.nlm.nih.gov/books/NBK459117/ SUPPORT Other
"is characterized by short stature, early-onset diffuse brachydactyly, round face, nasal hypoplasia, advanced bone age, and obesity."
GeneReviews describes the distinguishing skeletal pattern.
PMID:24363928 SUPPORT Human Clinical
"Two different genetic and phenotypic syndromes are now identified, both with a similar bone dysplasia: ADOHR, due to PRKAR1A defects, and ADOP4 (our denomination), due to PDE4D defects. The existence of GPCR-hormone resistance is typical of the ADOHR syndrome."
Separates the two acrodysostosis genes and names the hormone-resistance feature that distinguishes them from each other, which is the genotype dependence recorded in the distinguishing features above.
PMID:27589370 SUPPORT Model Organism
"This model, the first describing the germline expression of a PRKAR1A mutation causing dominant repression of cAMP-dependent PKA, reproduced the main features of ACRDYS1 in humans."
Repressing PKA downstream of Gs-alpha reproduces the skeletal phenotype in mouse, which is why this differential is a cAMP-pathway phenocopy rather than a GNAS-specific finding.
Isolated brachydactyly type E
Overlapping Features HOXD13 or PTHLH variants can produce shortened metacarpals and metatarsals.
Distinguishing Features
  • Ectopic ossification and intellectual disability are generally absent in the isolated phenotype; molecular testing distinguishes these pathway-related conditions.
Show evidence (2 references)
url:https://www.ncbi.nlm.nih.gov/books/NBK459117/ SUPPORT Other
"Some individuals have moderate short stature and round facies but do not have ectopic ossification or intellectual disability."
The isolated brachydactyly differential lacks key extraskeletal features.
PMID:34897794 SUPPORT Human Clinical
"Unfortunately, we could not find distinctive phenotypic features that might have led to an earlier clinical diagnosis, further highlighting the high degree of overlap among skeletal syndromes associated with brachydactyly and AHO-like features"
Five patients with an AHO-like skeletal phenotype turned out to carry PTHLH or TRPS1 variants, and the authors found no clinical feature that would have separated them beforehand. This is the reason molecular testing, not the skeletal pattern, is recorded as the discriminator. TRPS1 disease is not curated as a separate differential here; it adds sparse hair, a pear-shaped nose, and cone-shaped epiphyses.
🔬

Clinical Trials

4
NCT00209235 NOT_APPLICABLE ACTIVE_NOT_RECRUITING
AHO natural-history and cognitive/behavioral follow-up explicitly includes mutation-confirmed PPHP. The growth-hormone substudy is restricted to PHP1A and must not be interpreted as PPHP efficacy evidence.
Show evidence (1 reference)
clinicaltrials:NCT00209235 SUPPORT Human Clinical
"We, the researchers, are following the natural history of Albright hereditary osteodystrophy."
The registry establishes ongoing natural-history research; API eligibility separates PPHP follow-up from the PHP1A GH arm.
NCT03761290 NOT_APPLICABLE TERMINATED
Observational glucose-homeostasis study enrolling PHP1A/PPHP participants and matched controls. The record reports 14 participants and termination because COVID precautions prevented healthy-control enrollment and funding ended.
Show evidence (1 reference)
clinicaltrials:NCT03761290 SUPPORT Human Clinical
"In this pilot study we will assess β-cell function in patients with PHP1A and pseudopseudohypoparathyroidism PPHP."
The protocol explicitly includes PPHP.
NCT00001242 NOT_APPLICABLE COMPLETED
Historical NIH study of vitamin D/PTH resistance and related disorders; eligibility explicitly includes PPHP or suspected PPHP. Its diagnostic evaluation and inclusion in other protocols are not a PPHP-specific intervention result.
Show evidence (1 reference)
clinicaltrials:NCT00001242 SUPPORT Human Clinical
"Patients will be tested with multiple indices of mineral metabolism to establish the diagnosis and examine the spectrum of the underlying disorder."
The registry describes diagnostic characterization of related mineral-metabolism conditions.
NCT04551170 PHASE_II ACTIVE_NOT_RECRUITING
Related PHP/AHO trial of the PDE inhibitor theophylline in children aged 2–12 years, with obesity required. The protocol targets cAMP signaling, BMI and epiphyseal closure. Broad clinical criteria do not establish a molecular PPHP subgroup or PPHP skeletal efficacy.
Show evidence (1 reference)
clinicaltrials:NCT04551170 SUPPORT Human Clinical
"This phase 2 clinical trial and open-label extension study will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism."
A registered cAMP-pathway trial exists in the related PHP/AHO population.
🧫

Experimental Models

1
Patient-derived dermal fibroblast microarrays PRIMARY_CELL_CULTURE
Affymetrix U133 Plus 2.0 comparisons across five participants identified 23 shared differentially expressed genes, including SFRP2. P2 contributes to two contrasts and is the mother of P3; age, sex, subtype, relatedness and lesion burden can confound expression. This is patient-cell omics, but not fresh-lesion single-cell lineage proof. No raw accession was identified in the inspected paper.
Cell source
Dermal fibroblast cultures from three PPHP, one PHP1A and one POH participant
Pathograph links
Dermal and subcutaneous ectopic bone formation measures Expression correlates with lesion burden but does not isolate causal human progenitors.
Limitations: Cultured dermal fibroblasts may differ from fresh lesion progenitors. The five-person comparisons mix PPHP, PHP1A and POH and are confounded by age, sex, relatedness, lesion burden and repeated use of one participant.
Show evidence (1 reference)
PMID:40256763 SUPPORT In Vitro
"In all 3 comparisons (P1 × P2, P3 × P2, and P4 × P5), a participant with the greater number (and size as well) of SCOs was compared to a participant with fewer or no ossifications."
Cultured fibroblast microarrays include three PPHP participants, one PHP1A participant and one POH participant. Comparisons are small, heterogeneous and partly related, not independent patient-level replication.
Show evidence (1 reference)
PMID:40256763 SUPPORT In Vitro
"In all 3 comparisons (P1 × P2, P3 × P2, and P4 × P5), a participant with the greater number (and size as well) of SCOs was compared to a participant with fewer or no ossifications."
Cultured fibroblast microarrays include three PPHP participants, one PHP1A participant and one POH participant. Comparisons are small, heterogeneous and partly related, not independent patient-level replication.
🐁

Animal Models

5
Parent-specific heterozygous Gnas exon-1 mouse
Exon-1 disruption separates Gs-alpha from other locus transcripts. Both parental forms develop superficial ossifications, while endocrine and metabolic phenotypes depend on parental origin. Later bone-remodeling differences were predominantly female and should not be converted into an established human PPHP osteoporosis phenotype.
Species
Mouse
Genotype
GnasE1+/- with maternal or paternal inheritance
Pathograph links
Reduced Gs-alpha dosage in biallelic tissues partially recapitulates Exon-1 heterozygosity models partial Gs-alpha loss; expression studies identify biallelic tissues.
Limitations: Species, zygosity and tissue context limit direct extrapolation to human heterozygous PPHP.
Show evidence (1 reference)
PMID:16099856 SUPPORT Model Organism
"Galphas protein and mRNA expression was consistent with paternal imprinting in the renal cortex and thyroid, but there was no imprinting in renal medulla, heart, or adipose."
The exon-1 study directly evaluates tissue-specific Gs-alpha expression in the described model; the separate exon-2 chimera is not used as its experimental provenance.
Dermal and subcutaneous ectopic bone formation partially recapitulates Both parental forms develop AHO-like ectopic bone.
Limitations: Species, zygosity and tissue context limit direct extrapolation to human heterozygous PPHP.
Show evidence (1 reference)
PMID:21747923 SUPPORT Model Organism
"Gnas(E1-/+) mice develop SCO features that are similar to those observed in AHO patients"
Heterozygous Gnas exon-1 mice reproduce superficial ectopic bone.
Show evidence (2 references)
PMID:35079678 SUPPORT Model Organism
"GnasE1+/-p mice exhibited reduced bone parameters due to impaired bone formation and enhanced bone resorption."
Predominantly female mouse effects show that a universal complete-knockout bone model is inadequate.
PMID:21747923 SUPPORT Model Organism
"Gnas(E1-/+) mice develop SCO features that are similar to those observed in AHO patients"
Heterozygous Gnas exon-1 mice reproduce superficial ectopic bone.
Heterozygous chondrocyte chimera
Approximately half-normal Gs-alpha RNA after either parental disruption is accompanied by modest premature hypertrophy. The design does not reproduce human digit-selective brachydactyly.
Species
Mouse
Genotype
Chimeric wild-type and Gnas+/E2- growth plates
Pathograph links
Premature chondrocyte hypertrophy partially recapitulates A dosage-relevant cellular phenotype supports the growth-plate mechanism.
Limitations: Species, zygosity and tissue context limit direct extrapolation to human heterozygous PPHP.
Show evidence (1 reference)
PMID:15459318 SUPPORT Model Organism
"Hypertrophy of Gnas(+/E2-) chondrocytes was modestly but significantly premature in chimeric growth plates of mice containing wild-type and Gnas(+/E2-) cells."
The heterozygous chimera shows modest premature hypertrophy; it does not establish human digit selectivity.
Show evidence (1 reference)
PMID:15459318 SUPPORT Model Organism
"Hypertrophy of Gnas(+/E2-) chondrocytes was modestly but significantly premature in chimeric growth plates of mice containing wild-type and Gnas(+/E2-) cells."
The heterozygous chimera shows modest premature hypertrophy; it does not establish human digit selectivity.
Complete and partial chondrocyte-specific Gnas deletion
Complete deletion causes severe growth-plate defects and perinatal death; heterozygotes in the same study have no overt phenotype. These are pathway-necessity and negative dosage observations, respectively.
Species
Mouse
Genotype
Col2a1-Cre; Gnas floxed null or heterozygous
Pathograph links
Reduced PTHrP-dependent chondrocyte signaling perturbs Complete deletion perturbs the PTHrP/Gs-alpha pathway.
Limitations: Species, zygosity and tissue context limit direct extrapolation to human heterozygous PPHP.
Show evidence (1 reference)
PMID:15765186 SUPPORT Model Organism
"Mice with complete chondrocyte-specific G(s)alpha deficiency (homozygotes) died within minutes after birth and had severe epiphyseal and growth plate defects with shortening of the proliferative zone and accelerated hypertrophic differentiation of growth plate chondrocytes, a phenotype similar..."
Complete conditional knockout establishes pathway necessity, whereas heterozygotes in this separate model had no overt phenotype.
Premature chondrocyte hypertrophy fails to recapitulate Partial deletion in this model does not reproduce the overt skeletal phenotype.
Limitations: Species, zygosity and tissue context limit direct extrapolation to human heterozygous PPHP.
Show evidence (1 reference)
PMID:15765186 SUPPORT Model Organism
"Mice with partial G(s)alpha deficiency (heterozygotes) exhibited no phenotype."
Complete conditional knockout establishes pathway necessity, whereas heterozygotes in this separate model had no overt phenotype.
Show evidence (1 reference)
PMID:15765186 SUPPORT Model Organism
"Mice with complete chondrocyte-specific G(s)alpha deficiency (homozygotes) died within minutes after birth and had severe epiphyseal and growth plate defects with shortening of the proliferative zone and accelerated hypertrophic differentiation of growth plate chondrocytes, a phenotype similar..."
Complete conditional knockout establishes pathway necessity, whereas heterozygotes in this separate model had no overt phenotype.
AHO alpha-SMA lineage tracing and Sfrp2 modifier mouse
Alpha-SMA-labelled cells contribute to ossifications after long-term tracing; initial labels include dermal sheath, arrector pili and vessels. Sfrp2 deletion accelerates lesions in male AHO mice, with no corresponding significant female effect. Fate mapping does not prove selective lineage necessity or human cell identity.
Species
Mouse
Genotype
GnasE1+/-; alphaSMACreERT2; Ai9, with or without Sfrp2 deletion
Pathograph links
Dermal and subcutaneous ectopic bone formation partially recapitulates Lineage tracing identifies contributing cells and modifier perturbation changes lesion burden.
Limitations: Species, zygosity and tissue context limit direct extrapolation to human heterozygous PPHP.
Show evidence (2 references)
PMID:40256763 SUPPORT Model Organism
"Here we show that SCO formation occurs due to inappropriate expansion and osteogenic differentiation of cells that express alpha-smooth muscle actin and that are located within the dermal sheath."
Mouse alpha-SMA fate mapping supports a dermal-sheath contribution; initial labeling includes additional alpha-SMA populations and does not establish human cell identity.
+ 1 more reference
Show evidence (2 references)
PMID:40256763 SUPPORT Model Organism
"Here we show that SCO formation occurs due to inappropriate expansion and osteogenic differentiation of cells that express alpha-smooth muscle actin and that are located within the dermal sheath."
Mouse alpha-SMA fate mapping supports a dermal-sheath contribution; initial labeling includes additional alpha-SMA populations and does not establish human cell identity.
PMID:40256763 SUPPORT Model Organism
"elimination of Sfrp2 in male AHO mice leads to earlier development, greater severity, and acceleration of formation of SCOs."
Sfrp2 deletion worsens lesions in male AHO mice, supporting a protective modifier rather than an obligatory pathogenic SFRP2 increase.
Conditional Gnas-null POH models
Related POH models support Hedgehog activation, YAP-SHH paracrine recruitment and effects of the mutant host environment on wild-type cells. Null dosage and deep progressive disease limit transfer to heterozygous superficial PPHP.
Species
Mouse
Genotype
Conditional Gnas-null mesenchymal cells and host tissues
Pathograph links
Hedgehog-dependent osteogenic activation partially recapitulates Hedgehog perturbation affects ectopic osteogenesis.
Limitations: Species, zygosity and tissue context limit direct extrapolation to human heterozygous PPHP.
Show evidence (1 reference)
PMID:24076664 SUPPORT Model Organism
"Here we demonstrate that Gαs restricts bone formation to the skeleton by inhibiting Hedgehog signaling in mesenchymal progenitor cells."
Perturbation studies support a Hedgehog-dependent mechanism in Gnas-null POH models; direct transfer to heterozygous human PPHP remains provisional.
YAP-SHH paracrine recruitment partially recapitulates Cell and host manipulations interrogate paracrine propagation.
Limitations: Species, zygosity and tissue context limit direct extrapolation to human heterozygous PPHP.
Show evidence (2 references)
PMID:34162750 SUPPORT Model Organism
"We further showed that loss of Gnas led to activation of YAP transcription activity, which directly drove Shh expression."
Gnas-null mesenchymal cells support YAP-SHH-mediated propagation; the model is not equivalent to heterozygous PPHP.
+ 1 more reference
Show evidence (3 references)
PMID:24076664 SUPPORT Model Organism
"Here we demonstrate that Gαs restricts bone formation to the skeleton by inhibiting Hedgehog signaling in mesenchymal progenitor cells."
Perturbation studies support a Hedgehog-dependent mechanism in Gnas-null POH models; direct transfer to heterozygous human PPHP remains provisional.
PMID:34162750 SUPPORT Model Organism
"We further showed that loss of Gnas led to activation of YAP transcription activity, which directly drove Shh expression."
Gnas-null mesenchymal cells support YAP-SHH-mediated propagation; the model is not equivalent to heterozygous PPHP.
PMID:33574833 SUPPORT Model Organism
"We found that mutant cells in a Gnas-null tissue environment induced a robust HO response while little/no HO was detected in control hosts."
Mutant-host transplantation experiments support a permissive non-cell-autonomous environment in a POH model.
{ }

Source YAML

click to show 
name: Pseudopseudohypoparathyroidism
creation_date: '2026-05-10T18:13:23Z'
description: >-
  Pseudopseudohypoparathyroidism (PPHP) is a GNAS-related disorder in which
  patients have Albright hereditary osteodystrophy features, such as
  brachydactyly, short stature, rounded face, and ectopic ossification, but
  classically lack parathyroid hormone resistance.
category: Genetic
parents:
- Disorder of GNAS Inactivation
- Acromelic Dysplasia
synonyms:
- PPHP
- Pseudo-pseudohypoparathyroidism
- AHO-PPHP syndrome
- Albright hereditary osteodystrophy-PPHP syndrome
disease_term:
  preferred_term: pseudopseudohypoparathyroidism
  term:
    id: MONDO:0012912
    label: pseudopseudohypoparathyroidism
prevalence:
- population: Europe point prevalence
  measure_type: POINT_PREVALENCE
  prevalence_class: UNKNOWN
  percentage: Unknown
  evidence:
  - reference: ORPHA:79445
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Unknown | Europe | Point prevalence | ORPHANET
    explanation: Orphanet reports unknown point prevalence for PPHP in Europe.
    reference_title: Pseudopseudohypoparathyroidism
mechanistic_hypotheses:
- hypothesis_group_id: pphp_parent_of_origin_model
  hypothesis_label: Paternal GNAS Loss-of-Function Model
  status: CANONICAL
  description: >-
    A paternal GNAS coding loss-of-function variant reduces Gs-alpha dosage in biallelic tissues,
    producing AHO skeletal and soft-tissue features while usually sparing classic renal PTH resistance
    because of pre-existing tissue-specific imprinting.
  notes: >-
    Canonical after review of the OpenScientist synthesis. Renal imprinting context is distinct
    from the PPHP mutation-driven causal path; STX16 imprinting-establishment experiments concern
    PHP1B. Human thyroid imprinting is incomplete and fetal bulk renal cortex can show biallelic
    expression, so mouse tissue results cannot be made universal across human cells and ages.
    Rare paternal-variant hormone-resistance cases exist. Severe early obesity is typically maternal-variant
    associated, but universal PPHP leanness is not established. Shared-exon XL-alpha-s effects
    are variant-dependent modifiers, and PPHP, POH and osteoma cutis remain distinguishable phenotypes.
  evidence:
  - reference: PMID:9671744
    reference_title: Variable and tissue-specific hormone resistance in heterotrimeric Gs protein alpha-subunit (Gsalpha) knockout mice is due to tissue-specific imprinting of the gsalpha gene.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Gsalpha expression in the renal cortex (the site of PTH action) is markedly reduced in m-/+ but not in +/p- mice
    explanation: Maternal versus paternal disruption demonstrates the renal parent-of-origin effect in mice.
  - reference: PMID:16099856
    reference_title: A mouse model of albright hereditary osteodystrophy generated by targeted disruption of exon 1 of the Gnas gene.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Heterozygous mice that inherited the disruption maternally (-m/+) exhibited PTH and TSH resistance, whereas those with paternal inheritance (+/-p) had normal hormone responsiveness
    explanation: Exon-1-specific disruption separates Gs-alpha from effects on other GNAS transcripts.
  - &id001
    reference: PMID:15459318
    reference_title: Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Gsalpha mRNA expression detected by real-time RT-PCR analysis was reduced to approximately half that of the wild-type in both paternal and maternal Gnas(+/E2-) growth plate chondrocytes, indicating biallelic expression of Gsalpha in these cells.
    explanation: Approximately half-normal RNA after either parental disruption supports biallelic growth-plate dosage.
  - reference: PMID:23884777
    reference_title: Paternal GNAS mutations lead to severe intrauterine growth retardation (IUGR) and provide evidence for a role of XLαs in fetal development.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: birth weights were lower with paternal GNAS mutations affecting exons 2-13 than with exon 1/intron 1 mutations.
    explanation: Birth parameters from 26 PPHP/POH and 29 PHP-Ia patients support an exon-class association, not isolated proof that XL-alpha-s determines fetal growth.
  - reference: PMID:22215617
    reference_title: New mutations at the imprinted Gnas cluster show gene dosage effects of Gsα in postnatal growth and implicate XLαs in bone and fat metabolism but not in suckling.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: paternal inheritance of Ex1A-T results in an increased metabolic rate and reductions in fat mass, leptin, and bone mineral density attributable to loss of XLαs
    explanation: The engineered mouse allele supports isoform-dependent effects but also changes locus dosage; human effects are variant-dependent.
  - reference: PMID:12147228
    reference_title: Paternal imprinting of Galpha(s) in the human thyroid as the basis of TSH resistance in pseudohypoparathyroidism type 1a.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: with paternal Galpha(s) transcripts accounting for only 25.9-40.4%.
    explanation: Eight normal human thyroid samples showed incomplete paternal suppression, contradicting the report claim that human tissue imprinting has only been studied in pituitary.
  - reference: PMID:11600515
    reference_title: 'Galphas transcripts are biallelically expressed in the human kidney cortex: implications for pseudohypoparathyroidism type 1b.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Galphas transcripts are biallelically expressed in human kidney cortex.
    explanation: Fetal human renal-cortex bulk RNA does not directly test mature proximal-tubule-specific imprinting.
- hypothesis_group_id: aho_developmental_model
  hypothesis_label: AHO Developmental Tissue Model
  status: CANONICAL
  description: >-
    Reduced Gs-alpha signaling disrupts growth-plate maturation and mesenchymal osteogenic programs.
    Separate growth and ectopic-ossification pathways explain core AHO skeletal features, while
    selective digit involvement and human lesion-cell mechanisms remain incompletely resolved.
  notes: >-
    Canonical core with qualified experimental branches after OpenScientist assessment. Heterozygous
    chimera evidence is distinguished from complete conditional knockouts. Mouse dermal-sheath
    lineage tracing is not human lineage proof. Hedgehog, YAP-SHH and microenvironment studies
    in POH models add mechanisms beyond a simple adipogenic-to-osteogenic switch. The 2025 study
    includes a small mixed PPHP/PHP1A/POH fibroblast microarray, contrary to the report omics-absence
    claim. SFRP2 deletion worsens ossification in male AHO mice, indicating a protective modifier;
    recombinant SFRP2 did not rescue explants. Somatic second hits remain hypothetical. No established
    PPHP skeletal disease-modifying therapy follows from these studies.
  evidence:
  - *id001
  - reference: PMID:15459318
    reference_title: Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Hypertrophy of Gnas(+/E2-) chondrocytes was modestly but significantly premature in chimeric growth plates of mice containing wild-type and Gnas(+/E2-) cells.
    explanation: The heterozygous chimera shows modest premature hypertrophy; it does not establish human digit selectivity.
  - reference: PMID:15765186
    reference_title: Chondrocyte-specific knockout of the G protein G(s)alpha leads to epiphyseal and growth plate abnormalities and ectopic chondrocyte formation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Mice with complete chondrocyte-specific G(s)alpha deficiency (homozygotes) died within minutes after birth and had severe epiphyseal and growth plate defects with shortening of the proliferative zone and accelerated hypertrophic differentiation of growth plate chondrocytes, a phenotype similar to that of PTH/PTH-related peptide (PTHrP) receptor knockout mice.
    explanation: Complete conditional knockout establishes pathway necessity, whereas heterozygotes in this separate model had no overt phenotype.
  - reference: PMID:22511293
    reference_title: Paternally inherited gsα mutation impairs adipogenesis and potentiates a lean phenotype in vivo.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Impaired adipocyte differentiation was rescued by an adenylyl cyclase activator, forskolin, and provided evidence that Gsα-cAMP signals are necessary in early stages of this process.
    explanation: cAMP stimulation rescues impaired adipogenesis in paternal-mutant mouse stromal cells; the human lesion mechanism is not a proven binary fate switch.
  - reference: PMID:40256763
    reference_title: Alpha-smooth muscle actin-expressing dermal sheath cells are a major cellular contributor to heterotopic subcutaneous ossifications in a mouse model of Albright hereditary osteodystrophy.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Here we show that SCO formation occurs due to inappropriate expansion and osteogenic differentiation of cells that express alpha-smooth muscle actin and that are located within the dermal sheath.
    explanation: Mouse alpha-SMA fate mapping supports a dermal-sheath contribution; initial labeling includes additional alpha-SMA populations and does not establish human cell identity.
  - reference: PMID:24076664
    reference_title: Activation of Hedgehog signaling by loss of GNAS causes heterotopic ossification.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Here we demonstrate that Gαs restricts bone formation to the skeleton by inhibiting Hedgehog signaling in mesenchymal progenitor cells.
    explanation: Perturbation studies support a Hedgehog-dependent mechanism in Gnas-null POH models; direct transfer to heterozygous human PPHP remains provisional.
  - reference: PMID:24076664
    reference_title: Activation of Hedgehog signaling by loss of GNAS causes heterotopic ossification.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In progressive osseous heteroplasia, a human disease caused by null mutations in GNAS, which encodes Gαs, Hedgehog signaling is upregulated in ectopic osteoblasts and progenitor cells.
    explanation: Human lesion evidence is from POH, a related but distinct GNAS ossification disorder.
  - reference: PMID:34162750
    reference_title: A self-amplifying loop of YAP and SHH drives formation and expansion of heterotopic ossification.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We further showed that loss of Gnas led to activation of YAP transcription activity, which directly drove Shh expression.
    explanation: Gnas-null mesenchymal cells support YAP-SHH-mediated propagation; the model is not equivalent to heterozygous PPHP.
  - reference: PMID:37014531
    reference_title: Variable Bone Phenotypes in Patients with Pseudohypoparathyroidism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Compared with normal controls, patients with PHP may exhibit similar, increased, or decreased bone mineral density.
    explanation: >-
      Human bone density in this disease family runs in both directions, which is why the skeletal
      arm of this model is stated as disrupted Gs-alpha-dependent growth and remodeling rather than
      as a single predicted bone-mass phenotype. The review covers PHP subtypes rather than a
      genotyped PPHP-only series.
pathophysiology:
- name: Paternal GNAS coding loss of function
  description: A heterozygous inactivating GNAS coding variant on the paternal chromosome causes the classical PPHP phenotype. It can be inherited or de novo. Pre-existing tissue-specific imprinting usually preserves sufficient maternal renal Gs-alpha signaling; the variant does not itself create normal imprinting or an STX16 deletion.
  evidence:
  - reference: PMID:15711092
    supports: SUPPORT
    evidence_source: OTHER
    snippet: PHP-Ia and PPHP are caused by heterozygous inactivating mutations in those exons of GNAS encoding the alpha subunit of the stimulatory guanine nucleotide-binding protein (Gsalpha)
    explanation: This supports heterozygous inactivating GNAS coding variants as causal for PPHP.
    reference_title: GNAS locus and pseudohypoparathyroidism.
  downstream:
  - target: Reduced Gs-alpha dosage in biallelic tissues
    description: Loss of one expressed Gs-alpha allele reduces dosage in biallelic skeletal and mesenchymal contexts.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:15459318
      reference_title: Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Gsalpha mRNA expression detected by real-time RT-PCR analysis was reduced to approximately half that of the wild-type in both paternal and maternal Gnas(+/E2-) growth plate chondrocytes, indicating biallelic expression of Gsalpha in these cells.
      explanation: Approximately half-normal RNA after either parental disruption supports biallelic growth-plate dosage.
  - target: Reduced XL-alpha-s function in shared-exon variants
    description: Variants involving shared exons can additionally impair the paternally expressed XL-alpha-s isoform; functional consequences depend on the variant.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:23884777
      reference_title: Paternal GNAS mutations lead to severe intrauterine growth retardation (IUGR) and provide evidence for a role of XLαs in fetal development.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: birth weights were lower with paternal GNAS mutations affecting exons 2-13 than with exon 1/intron 1 mutations.
      explanation: Birth parameters from 26 PPHP/POH and 29 PHP-Ia patients support an exon-class association, not isolated proof that XL-alpha-s determines fetal growth.
    - reference: PMID:22215617
      reference_title: New mutations at the imprinted Gnas cluster show gene dosage effects of Gsα in postnatal growth and implicate XLαs in bone and fat metabolism but not in suckling.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: paternal inheritance of Ex1A-T results in an increased metabolic rate and reductions in fat mass, leptin, and bone mineral density attributable to loss of XLαs
      explanation: The engineered mouse allele supports isoform-dependent effects but also changes locus dosage; human effects are variant-dependent.
  genes:
  - preferred_term: GNAS
    term:
      id: hgnc:4392
      label: GNAS
- name: Reduced Gs-alpha dosage in biallelic tissues
  description: Reduced Gs-alpha dosage impairs receptor coupling to adenylyl cyclase and cAMP signaling. Biallelic expression is demonstrated in mouse growth-plate chondrocytes; tissue, developmental stage and parent of origin can still modify downstream responses.
  evidence:
  - reference: PMID:15459318
    reference_title: Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Gsalpha mRNA expression detected by real-time RT-PCR analysis was reduced to approximately half that of the wild-type in both paternal and maternal Gnas(+/E2-) growth plate chondrocytes, indicating biallelic expression of Gsalpha in these cells.
    explanation: Approximately half-normal RNA after either parental disruption supports biallelic growth-plate dosage.
  downstream:
  - target: Reduced PTHrP-dependent chondrocyte signaling
    description: Reduced Gs-alpha weakens the PTHrP receptor signal that restrains chondrocyte maturation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:15459318
      reference_title: Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Hypertrophy of Gnas(+/E2-) chondrocytes was modestly but significantly premature in chimeric growth plates of mice containing wild-type and Gnas(+/E2-) cells.
      explanation: The heterozygous chimera shows modest premature hypertrophy; it does not establish human digit selectivity.
    - reference: PMID:15765186
      reference_title: Chondrocyte-specific knockout of the G protein G(s)alpha leads to epiphyseal and growth plate abnormalities and ectopic chondrocyte formation.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Mice with complete chondrocyte-specific G(s)alpha deficiency (homozygotes) died within minutes after birth and had severe epiphyseal and growth plate defects with shortening of the proliferative zone and accelerated hypertrophic differentiation of growth plate chondrocytes, a phenotype similar to that of PTH/PTH-related peptide (PTHrP) receptor knockout mice.
      explanation: Complete conditional knockout establishes pathway necessity, whereas heterozygotes in this separate model had no overt phenotype.
  - target: Mesenchymal osteogenic differentiation bias
    description: Reduced cAMP shifts mesenchymal differentiation toward osteogenic programs in experimental systems.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:22511293
      reference_title: Paternally inherited gsα mutation impairs adipogenesis and potentiates a lean phenotype in vivo.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Msh homeobox 2, an early osteogenic marker, runt-related transcription factor 2, an osteogenic transcription factor, and osteocalcin, a marker of terminal osteogenic differentiation were all expressed at higher levels in Gsα+/p− ASCs during adipogenic induction compared to WT ASCs (Fig. 5).
      explanation: Increased osteogenic-marker expression supports a progenitor differentiation bias; absent mineralization under these culture conditions limits claims of completed osteogenesis.
  - target: Hedgehog-dependent osteogenic activation
    description: Gnas inactivation releases restraint of Hedgehog osteogenic signaling in POH models.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:24076664
      reference_title: Activation of Hedgehog signaling by loss of GNAS causes heterotopic ossification.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Here we demonstrate that Gαs restricts bone formation to the skeleton by inhibiting Hedgehog signaling in mesenchymal progenitor cells.
      explanation: Perturbation studies support a Hedgehog-dependent mechanism in Gnas-null POH models; direct transfer to heterozygous human PPHP remains provisional.
    - reference: PMID:24076664
      reference_title: Activation of Hedgehog signaling by loss of GNAS causes heterotopic ossification.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: In progressive osseous heteroplasia, a human disease caused by null mutations in GNAS, which encodes Gαs, Hedgehog signaling is upregulated in ectopic osteoblasts and progenitor cells.
      explanation: Human lesion evidence is from POH, a related but distinct GNAS ossification disorder.
  - target: YAP-SHH paracrine recruitment
    description: Gnas loss activates YAP-dependent SHH production in related POH models.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:34162750
      reference_title: A self-amplifying loop of YAP and SHH drives formation and expansion of heterotopic ossification.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: We further showed that loss of Gnas led to activation of YAP transcription activity, which directly drove Shh expression.
      explanation: Gnas-null mesenchymal cells support YAP-SHH-mediated propagation; the model is not equivalent to heterozygous PPHP.
  biological_processes:
  - preferred_term: cAMP/PKA signal transduction
    term:
      id: GO:0141156
      label: cAMP/PKA signal transduction
- name: Reduced PTHrP-dependent chondrocyte signaling
  description: Reduced PTHrP/Gs-alpha/cAMP/PKA signaling removes a restraint on growth-plate chondrocyte differentiation. Complete knockout is much more severe than PPHP; dosage-relevant support comes from heterozygous chimeras.
  evidence:
  - reference: PMID:15459318
    reference_title: Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Hypertrophy of Gnas(+/E2-) chondrocytes was modestly but significantly premature in chimeric growth plates of mice containing wild-type and Gnas(+/E2-) cells.
    explanation: The heterozygous chimera shows modest premature hypertrophy; it does not establish human digit selectivity.
  - reference: PMID:15765186
    reference_title: Chondrocyte-specific knockout of the G protein G(s)alpha leads to epiphyseal and growth plate abnormalities and ectopic chondrocyte formation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Mice with complete chondrocyte-specific G(s)alpha deficiency (homozygotes) died within minutes after birth and had severe epiphyseal and growth plate defects with shortening of the proliferative zone and accelerated hypertrophic differentiation of growth plate chondrocytes, a phenotype similar to that of PTH/PTH-related peptide (PTHrP) receptor knockout mice.
    explanation: Complete conditional knockout establishes pathway necessity, whereas heterozygotes in this separate model had no overt phenotype.
  downstream:
  - target: Premature chondrocyte hypertrophy
    description: Reduced receptor signaling advances the transition into hypertrophy.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:15459318
      reference_title: Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Hypertrophy of Gnas(+/E2-) chondrocytes was modestly but significantly premature in chimeric growth plates of mice containing wild-type and Gnas(+/E2-) cells.
      explanation: The heterozygous chimera shows modest premature hypertrophy; it does not establish human digit selectivity.
    - reference: PMID:15765186
      reference_title: Chondrocyte-specific knockout of the G protein G(s)alpha leads to epiphyseal and growth plate abnormalities and ectopic chondrocyte formation.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Mice with complete chondrocyte-specific G(s)alpha deficiency (homozygotes) died within minutes after birth and had severe epiphyseal and growth plate defects with shortening of the proliferative zone and accelerated hypertrophic differentiation of growth plate chondrocytes, a phenotype similar to that of PTH/PTH-related peptide (PTHrP) receptor knockout mice.
      explanation: Complete conditional knockout establishes pathway necessity, whereas heterozygotes in this separate model had no overt phenotype.
  biological_processes:
  - preferred_term: cAMP/PKA signal transduction
    term:
      id: GO:0141156
      label: cAMP/PKA signal transduction
  cell_types:
  - preferred_term: chondrocyte
    term:
      id: CL:0000138
      label: chondrocyte
- name: Premature chondrocyte hypertrophy
  description: Heterozygous chimeric chondrocytes undergo modestly premature hypertrophy. Complete chondrocyte deletion shortens the proliferative zone and causes perinatal lethality, which must not be equated with heterozygous human disease.
  evidence:
  - reference: PMID:15459318
    reference_title: Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Hypertrophy of Gnas(+/E2-) chondrocytes was modestly but significantly premature in chimeric growth plates of mice containing wild-type and Gnas(+/E2-) cells.
    explanation: The heterozygous chimera shows modest premature hypertrophy; it does not establish human digit selectivity.
  - reference: PMID:15765186
    reference_title: Chondrocyte-specific knockout of the G protein G(s)alpha leads to epiphyseal and growth plate abnormalities and ectopic chondrocyte formation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Mice with complete chondrocyte-specific G(s)alpha deficiency (homozygotes) died within minutes after birth and had severe epiphyseal and growth plate defects with shortening of the proliferative zone and accelerated hypertrophic differentiation of growth plate chondrocytes, a phenotype similar to that of PTH/PTH-related peptide (PTHrP) receptor knockout mice.
    explanation: Complete conditional knockout establishes pathway necessity, whereas heterozygotes in this separate model had no overt phenotype.
  downstream:
  - target: Impaired longitudinal skeletal growth
    description: Accelerated maturation can shorten the period of longitudinal growth; the precise human digit-selective mechanism remains unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:15459318
      reference_title: Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Hypertrophy of Gnas(+/E2-) chondrocytes was modestly but significantly premature in chimeric growth plates of mice containing wild-type and Gnas(+/E2-) cells.
      explanation: The heterozygous chimera shows modest premature hypertrophy; it does not establish human digit selectivity.
    - reference: PMID:15765186
      reference_title: Chondrocyte-specific knockout of the G protein G(s)alpha leads to epiphyseal and growth plate abnormalities and ectopic chondrocyte formation.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Mice with complete chondrocyte-specific G(s)alpha deficiency (homozygotes) died within minutes after birth and had severe epiphyseal and growth plate defects with shortening of the proliferative zone and accelerated hypertrophic differentiation of growth plate chondrocytes, a phenotype similar to that of PTH/PTH-related peptide (PTHrP) receptor knockout mice.
      explanation: Complete conditional knockout establishes pathway necessity, whereas heterozygotes in this separate model had no overt phenotype.
  cell_types:
  - preferred_term: hypertrophic chondrocyte
    term:
      id: CL:0000743
      label: hypertrophic chondrocyte
- name: Impaired longitudinal skeletal growth
  description: Premature growth-plate maturation contributes to shortened metacarpals, metatarsals and adult stature. The preference for particular digits is not explained by current mouse experiments, and short stature can also reflect prenatal growth restriction or uncommon endocrine abnormalities.
  evidence:
  - reference: PMID:15459318
    reference_title: Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Hypertrophy of Gnas(+/E2-) chondrocytes was modestly but significantly premature in chimeric growth plates of mice containing wild-type and Gnas(+/E2-) cells.
    explanation: The heterozygous chimera shows modest premature hypertrophy; it does not establish human digit selectivity.
  - reference: PMID:15765186
    reference_title: Chondrocyte-specific knockout of the G protein G(s)alpha leads to epiphyseal and growth plate abnormalities and ectopic chondrocyte formation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Mice with complete chondrocyte-specific G(s)alpha deficiency (homozygotes) died within minutes after birth and had severe epiphyseal and growth plate defects with shortening of the proliferative zone and accelerated hypertrophic differentiation of growth plate chondrocytes, a phenotype similar to that of PTH/PTH-related peptide (PTHrP) receptor knockout mice.
    explanation: Complete conditional knockout establishes pathway necessity, whereas heterozygotes in this separate model had no overt phenotype.
  downstream:
  - target: Brachydactyly
    description: Reduced growth of selected tubular bones produces brachydactyly; regional susceptibility remains incompletely explained.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:15459318
      reference_title: Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Hypertrophy of Gnas(+/E2-) chondrocytes was modestly but significantly premature in chimeric growth plates of mice containing wild-type and Gnas(+/E2-) cells.
      explanation: The heterozygous chimera shows modest premature hypertrophy; it does not establish human digit selectivity.
    - reference: PMID:15765186
      reference_title: Chondrocyte-specific knockout of the G protein G(s)alpha leads to epiphyseal and growth plate abnormalities and ectopic chondrocyte formation.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Mice with complete chondrocyte-specific G(s)alpha deficiency (homozygotes) died within minutes after birth and had severe epiphyseal and growth plate defects with shortening of the proliferative zone and accelerated hypertrophic differentiation of growth plate chondrocytes, a phenotype similar to that of PTH/PTH-related peptide (PTHrP) receptor knockout mice.
      explanation: Complete conditional knockout establishes pathway necessity, whereas heterozygotes in this separate model had no overt phenotype.
  - target: Short stature
    description: Reduced longitudinal growth contributes to adult short stature.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:15459318
      reference_title: Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Hypertrophy of Gnas(+/E2-) chondrocytes was modestly but significantly premature in chimeric growth plates of mice containing wild-type and Gnas(+/E2-) cells.
      explanation: The heterozygous chimera shows modest premature hypertrophy; it does not establish human digit selectivity.
    - reference: PMID:15765186
      reference_title: Chondrocyte-specific knockout of the G protein G(s)alpha leads to epiphyseal and growth plate abnormalities and ectopic chondrocyte formation.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Mice with complete chondrocyte-specific G(s)alpha deficiency (homozygotes) died within minutes after birth and had severe epiphyseal and growth plate defects with shortening of the proliferative zone and accelerated hypertrophic differentiation of growth plate chondrocytes, a phenotype similar to that of PTH/PTH-related peptide (PTHrP) receptor knockout mice.
      explanation: Complete conditional knockout establishes pathway necessity, whereas heterozygotes in this separate model had no overt phenotype.
  mechanism_confidence: PROVISIONAL
  biological_processes:
  - preferred_term: endochondral bone growth
    term:
      id: GO:0003416
      label: endochondral bone growth
- name: Mesenchymal osteogenic differentiation bias
  description: Paternal-mutant mouse adipose stromal cells have reduced adipogenic differentiation and increased osteogenic markers, with forskolin rescue of adipogenesis. This is a progenitor fate bias, not proof that mature adipocytes become bone or that every PPHP patient is lean.
  evidence:
  - reference: PMID:22511293
    reference_title: Paternally inherited gsα mutation impairs adipogenesis and potentiates a lean phenotype in vivo.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Msh homeobox 2, an early osteogenic marker, runt-related transcription factor 2, an osteogenic transcription factor, and osteocalcin, a marker of terminal osteogenic differentiation were all expressed at higher levels in Gsα+/p− ASCs during adipogenic induction compared to WT ASCs (Fig. 5).
    explanation: Paternal-mutant mouse stromal cells express more osteogenic markers even under adipogenic induction. Neither genotype mineralized under those culture conditions, so this demonstrates a differentiation bias rather than completed ectopic bone formation.
  downstream:
  - target: Dermal and subcutaneous ectopic bone formation
    description: Osteogenic progenitor differentiation contributes to ectopic bone formation, with additional local signaling and tissue-environment effects.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:22511293
      reference_title: Paternally inherited gsα mutation impairs adipogenesis and potentiates a lean phenotype in vivo.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Msh homeobox 2, an early osteogenic marker, runt-related transcription factor 2, an osteogenic transcription factor, and osteocalcin, a marker of terminal osteogenic differentiation were all expressed at higher levels in Gsα+/p− ASCs during adipogenic induction compared to WT ASCs (Fig. 5).
      explanation: Increased osteogenic-marker expression supports a progenitor differentiation bias; absent mineralization under these culture conditions limits claims of completed osteogenesis.
    - reference: PMID:40256763
      reference_title: Alpha-smooth muscle actin-expressing dermal sheath cells are a major cellular contributor to heterotopic subcutaneous ossifications in a mouse model of Albright hereditary osteodystrophy.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Here we show that SCO formation occurs due to inappropriate expansion and osteogenic differentiation of cells that express alpha-smooth muscle actin and that are located within the dermal sheath.
      explanation: Mouse alpha-SMA fate mapping supports a dermal-sheath contribution; initial labeling includes additional alpha-SMA populations and does not establish human cell identity.
  mechanism_confidence: PROVISIONAL
  cell_types:
  - preferred_term: mesenchymal stem cell
    term:
      id: CL:0000134
      label: mesenchymal stem cell
  biological_processes:
  - preferred_term: osteoblast differentiation
    term:
      id: GO:0001649
      label: osteoblast differentiation
- name: Hedgehog-dependent osteogenic activation
  description: Gnas-loss models activate Hedgehog-dependent osteogenesis. Human POH lesions show pathway upregulation, but the necessity and extent of this mechanism in heterozygous superficial PPHP lesions are unproven.
  evidence:
  - reference: PMID:24076664
    reference_title: Activation of Hedgehog signaling by loss of GNAS causes heterotopic ossification.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Here we demonstrate that Gαs restricts bone formation to the skeleton by inhibiting Hedgehog signaling in mesenchymal progenitor cells.
    explanation: Perturbation studies support a Hedgehog-dependent mechanism in Gnas-null POH models; direct transfer to heterozygous human PPHP remains provisional.
  - reference: PMID:24076664
    reference_title: Activation of Hedgehog signaling by loss of GNAS causes heterotopic ossification.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In progressive osseous heteroplasia, a human disease caused by null mutations in GNAS, which encodes Gαs, Hedgehog signaling is upregulated in ectopic osteoblasts and progenitor cells.
    explanation: Human lesion evidence is from POH, a related but distinct GNAS ossification disorder.
  downstream:
  - target: Dermal and subcutaneous ectopic bone formation
    description: Hedgehog pathway activation promotes ectopic osteoblast differentiation in POH models.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:24076664
      reference_title: Activation of Hedgehog signaling by loss of GNAS causes heterotopic ossification.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Here we demonstrate that Gαs restricts bone formation to the skeleton by inhibiting Hedgehog signaling in mesenchymal progenitor cells.
      explanation: Perturbation studies support a Hedgehog-dependent mechanism in Gnas-null POH models; direct transfer to heterozygous human PPHP remains provisional.
    - reference: PMID:24076664
      reference_title: Activation of Hedgehog signaling by loss of GNAS causes heterotopic ossification.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: In progressive osseous heteroplasia, a human disease caused by null mutations in GNAS, which encodes Gαs, Hedgehog signaling is upregulated in ectopic osteoblasts and progenitor cells.
      explanation: Human lesion evidence is from POH, a related but distinct GNAS ossification disorder.
  mechanism_confidence: PROVISIONAL
  cell_types:
  - preferred_term: mesenchymal stem cell
    term:
      id: CL:0000134
      label: mesenchymal stem cell
  biological_processes:
  - preferred_term: osteoblast differentiation
    term:
      id: GO:0001649
      label: osteoblast differentiation
- name: YAP-SHH paracrine recruitment
  description: A YAP-SHH feedback circuit in Gnas-null mesenchymal cells recruits neighboring wild-type cells into osteogenesis. Transplantation studies also show that the mutant tissue environment affects lesion formation. These are POH-model mechanisms requiring confirmation in PPHP.
  evidence:
  - reference: PMID:34162750
    reference_title: A self-amplifying loop of YAP and SHH drives formation and expansion of heterotopic ossification.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We further showed that loss of Gnas led to activation of YAP transcription activity, which directly drove Shh expression.
    explanation: Gnas-null mesenchymal cells support YAP-SHH-mediated propagation; the model is not equivalent to heterozygous PPHP.
  - reference: PMID:33574833
    reference_title: Gnas Inactivation Alters Subcutaneous Tissues in Progression to Heterotopic Ossification.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We found that mutant cells in a Gnas-null tissue environment induced a robust HO response while little/no HO was detected in control hosts.
    explanation: Mutant-host transplantation experiments support a permissive non-cell-autonomous environment in a POH model.
  downstream:
  - target: Dermal and subcutaneous ectopic bone formation
    description: Paracrine recruitment and a permissive tissue environment expand heterotopic ossification in related models.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:34162750
      reference_title: A self-amplifying loop of YAP and SHH drives formation and expansion of heterotopic ossification.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: We further showed that loss of Gnas led to activation of YAP transcription activity, which directly drove Shh expression.
      explanation: Gnas-null mesenchymal cells support YAP-SHH-mediated propagation; the model is not equivalent to heterozygous PPHP.
    - reference: PMID:33574833
      reference_title: Gnas Inactivation Alters Subcutaneous Tissues in Progression to Heterotopic Ossification.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: We found that mutant cells in a Gnas-null tissue environment induced a robust HO response while little/no HO was detected in control hosts.
      explanation: Mutant-host transplantation experiments support a permissive non-cell-autonomous environment in a POH model.
  mechanism_confidence: PROVISIONAL
- name: Dermal and subcutaneous ectopic bone formation
  description: True intramembranous bone forms in skin and subcutaneous tissue, independently of the serum calcium-phosphate abnormality of PTH resistance. Alpha-SMA lineage tracing supports a dermal-sheath contribution in AHO mice. Progressive invasion of deep fascia and muscle suggests POH or an overlap phenotype rather than classical superficial PPHP.
  evidence:
  - reference: PMID:21747923
    reference_title: Heterotopic ossifications in a mouse model of albright hereditary osteodystrophy.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Gnas(E1-/+) mice develop SCO features that are similar to those observed in AHO patients
    explanation: Heterozygous Gnas exon-1 mice reproduce superficial ectopic bone.
  - reference: PMID:29059381
    reference_title: 'Ossifications in Albright Hereditary Osteodystrophy: Role of Genotype, Inheritance, Sex, Age, Hormonal Status, and BMI.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'RESULTS: Forty-seven of 67 participants (70.1%) had SCOs. Patients with PHP1A and PPHP had similar prevalences and degrees of ossification formation. Patients with frameshift and nonsense mutations had much more extensive SCOs than those with missense mutations. Males were affected more than females. There was no correlation with hormonal status or BMI.'
    explanation: The 67-person AHO cohort included 18 PPHP cases; ossification burden was similar between PPHP and PHP1A and did not correlate with BMI or hormone status.
  - reference: PMID:40256763
    reference_title: Alpha-smooth muscle actin-expressing dermal sheath cells are a major cellular contributor to heterotopic subcutaneous ossifications in a mouse model of Albright hereditary osteodystrophy.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Here we show that SCO formation occurs due to inappropriate expansion and osteogenic differentiation of cells that express alpha-smooth muscle actin and that are located within the dermal sheath.
    explanation: Mouse alpha-SMA fate mapping supports a dermal-sheath contribution; initial labeling includes additional alpha-SMA populations and does not establish human cell identity.
  downstream:
  - target: Ectopic ossification
    description: Formation of bone outside the skeleton produces the clinical lesions.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:21747923
      reference_title: Heterotopic ossifications in a mouse model of albright hereditary osteodystrophy.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Gnas(E1-/+) mice develop SCO features that are similar to those observed in AHO patients
      explanation: Heterozygous Gnas exon-1 mice reproduce superficial ectopic bone.
    - reference: PMID:29059381
      reference_title: 'Ossifications in Albright Hereditary Osteodystrophy: Role of Genotype, Inheritance, Sex, Age, Hormonal Status, and BMI.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'RESULTS: Forty-seven of 67 participants (70.1%) had SCOs. Patients with PHP1A and PPHP had similar prevalences and degrees of ossification formation. Patients with frameshift and nonsense mutations had much more extensive SCOs than those with missense mutations. Males were affected more than females. There was no correlation with hormonal status or BMI.'
      explanation: The 67-person AHO cohort included 18 PPHP cases; ossification burden was similar between PPHP and PHP1A and did not correlate with BMI or hormone status.
  - target: Osteoma cutis
    description: Dermal lesions can be classified as osteoma cutis.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:21747923
      reference_title: Heterotopic ossifications in a mouse model of albright hereditary osteodystrophy.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Gnas(E1-/+) mice develop SCO features that are similar to those observed in AHO patients
      explanation: Heterozygous Gnas exon-1 mice reproduce superficial ectopic bone.
    - reference: PMID:29059381
      reference_title: 'Ossifications in Albright Hereditary Osteodystrophy: Role of Genotype, Inheritance, Sex, Age, Hormonal Status, and BMI.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'RESULTS: Forty-seven of 67 participants (70.1%) had SCOs. Patients with PHP1A and PPHP had similar prevalences and degrees of ossification formation. Patients with frameshift and nonsense mutations had much more extensive SCOs than those with missense mutations. Males were affected more than females. There was no correlation with hormonal status or BMI.'
      explanation: The 67-person AHO cohort included 18 PPHP cases; ossification burden was similar between PPHP and PHP1A and did not correlate with BMI or hormone status.
  cell_types:
  - preferred_term: osteoblast
    term:
      id: CL:0000062
      label: osteoblast
  biological_processes:
  - preferred_term: ossification
    term:
      id: GO:0001503
      label: ossification
- name: Reduced XL-alpha-s function in shared-exon variants
  description: Shared-exon GNAS variants can affect XL-alpha-s as well as Gs-alpha. Lower birth weight in a mixed PPHP/POH cohort supports a fetal-growth modifier, but isoform-specific effects have not been isolated from mutation class or broader locus effects in patients.
  evidence:
  - reference: PMID:23884777
    reference_title: Paternal GNAS mutations lead to severe intrauterine growth retardation (IUGR) and provide evidence for a role of XLαs in fetal development.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: birth weights were lower with paternal GNAS mutations affecting exons 2-13 than with exon 1/intron 1 mutations.
    explanation: Birth parameters from 26 PPHP/POH and 29 PHP-Ia patients support an exon-class association, not isolated proof that XL-alpha-s determines fetal growth.
  - reference: PMID:22215617
    reference_title: New mutations at the imprinted Gnas cluster show gene dosage effects of Gsα in postnatal growth and implicate XLαs in bone and fat metabolism but not in suckling.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: paternal inheritance of Ex1A-T results in an increased metabolic rate and reductions in fat mass, leptin, and bone mineral density attributable to loss of XLαs
    explanation: The engineered mouse allele supports isoform-dependent effects but also changes locus dosage; human effects are variant-dependent.
  downstream:
  - target: Intrauterine growth retardation
    description: Reduced XL-alpha-s function is a plausible contributor to prenatal growth restriction; paternal exon-1 variants also lower birth weight.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:23884777
      reference_title: Paternal GNAS mutations lead to severe intrauterine growth retardation (IUGR) and provide evidence for a role of XLαs in fetal development.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: birth weights were lower with paternal GNAS mutations affecting exons 2-13 than with exon 1/intron 1 mutations.
      explanation: Birth parameters from 26 PPHP/POH and 29 PHP-Ia patients support an exon-class association, not isolated proof that XL-alpha-s determines fetal growth.
    - reference: PMID:22215617
      reference_title: New mutations at the imprinted Gnas cluster show gene dosage effects of Gsα in postnatal growth and implicate XLαs in bone and fat metabolism but not in suckling.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: paternal inheritance of Ex1A-T results in an increased metabolic rate and reductions in fat mass, leptin, and bone mineral density attributable to loss of XLαs
      explanation: The engineered mouse allele supports isoform-dependent effects but also changes locus dosage; human effects are variant-dependent.
  mechanism_confidence: PROVISIONAL
phenotypes:
- name: Round face
  category: Craniofacial
  frequency: FREQUENT
  description: Rounded facial appearance is a frequent AHO-associated feature in PPHP.
  phenotype_term:
    preferred_term: Round face
    term:
      id: HP:0000311
      label: Round face
  evidence:
  - reference: ORPHA:79445
    supports: SUPPORT
    evidence_source: OTHER
    snippet: HP:0000311 | Round face | Frequent (79-30%)
    explanation: Orphanet lists round face as frequent in PPHP.
    reference_title: Pseudopseudohypoparathyroidism
- name: Brachydactyly
  category: Skeletal
  frequency: FREQUENT
  diagnostic: true
  description: Shortened digits and metacarpals are frequent AHO findings in PPHP.
  phenotype_term:
    preferred_term: Brachydactyly
    term:
      id: HP:0001156
      label: Brachydactyly
  evidence:
  - reference: ORPHA:79445
    supports: SUPPORT
    evidence_source: OTHER
    snippet: HP:0001156 | Brachydactyly | Frequent (79-30%)
    explanation: Orphanet lists brachydactyly as frequent in PPHP.
    reference_title: Pseudopseudohypoparathyroidism
- name: Short stature
  category: Growth
  frequency: FREQUENT
  diagnostic: true
  description: Reduced linear growth is a frequent PPHP/AHO manifestation.
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: ORPHA:79445
    supports: SUPPORT
    evidence_source: OTHER
    snippet: HP:0004322 | Short stature | Frequent (79-30%)
    explanation: Orphanet lists short stature as frequent in PPHP.
    reference_title: Pseudopseudohypoparathyroidism
- name: Short 5th finger
  category: Skeletal
  frequency: FREQUENT
  description: Short fifth fingers are frequent in the PPHP hand phenotype.
  phenotype_term:
    preferred_term: Short 5th finger
    term:
      id: HP:0009237
      label: Short 5th finger
  evidence:
  - reference: ORPHA:79445
    supports: SUPPORT
    evidence_source: OTHER
    snippet: HP:0009237 | Short 5th finger | Frequent (79-30%)
    explanation: Orphanet lists short fifth finger as frequent in PPHP.
    reference_title: Pseudopseudohypoparathyroidism
- name: Short 4th metacarpal
  category: Skeletal
  frequency: FREQUENT
  description: Shortening of the fourth metacarpal is a frequent AHO hand finding.
  phenotype_term:
    preferred_term: Short 4th metacarpal
    term:
      id: HP:0010044
      label: Short 4th metacarpal
  evidence:
  - reference: ORPHA:79445
    supports: SUPPORT
    evidence_source: OTHER
    snippet: HP:0010044 | Short 4th metacarpal | Frequent (79-30%)
    explanation: Orphanet lists short fourth metacarpal as frequent in PPHP.
    reference_title: Pseudopseudohypoparathyroidism
- name: Short 5th metacarpal
  category: Skeletal
  frequency: FREQUENT
  description: Shortening of the fifth metacarpal is a frequent AHO hand finding.
  phenotype_term:
    preferred_term: Short 5th metacarpal
    term:
      id: HP:0010047
      label: Short 5th metacarpal
  evidence:
  - reference: ORPHA:79445
    supports: SUPPORT
    evidence_source: OTHER
    snippet: HP:0010047 | Short 5th metacarpal | Frequent (79-30%)
    explanation: Orphanet lists short fifth metacarpal as frequent in PPHP.
    reference_title: Pseudopseudohypoparathyroidism
- name: Short metatarsal
  category: Skeletal
  frequency: FREQUENT
  description: Short metatarsals extend the AHO short-tubular-bone pattern to the feet.
  phenotype_term:
    preferred_term: Short metatarsal
    term:
      id: HP:0010743
      label: Short metatarsal
  evidence:
  - reference: ORPHA:79445
    supports: SUPPORT
    evidence_source: OTHER
    snippet: HP:0010743 | Short metatarsal | Frequent (79-30%)
    explanation: Orphanet lists short metatarsal as frequent in PPHP.
    reference_title: Pseudopseudohypoparathyroidism
- name: Ectopic ossification
  category: Skeletal
  frequency: FREQUENT
  diagnostic: true
  description: True bone develops in skin or subcutaneous tissue. Burden can increase with age and is not explained by elevated calcium, phosphate, PTH or BMI. Deep progressive extension warrants assessment for POH overlap.
  phenotype_term:
    preferred_term: Ectopic ossification
    term:
      id: HP:0011986
      label: Ectopic ossification
  evidence:
  - reference: ORPHA:79445
    supports: SUPPORT
    evidence_source: OTHER
    snippet: HP:0011986 | Ectopic ossification | Frequent (79-30%)
    explanation: Orphanet lists ectopic ossification as frequent in PPHP.
    reference_title: Pseudopseudohypoparathyroidism
  - reference: PMID:29059381
    reference_title: 'Ossifications in Albright Hereditary Osteodystrophy: Role of Genotype, Inheritance, Sex, Age, Hormonal Status, and BMI.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'RESULTS: Forty-seven of 67 participants (70.1%) had SCOs. Patients with PHP1A and PPHP had similar prevalences and degrees of ossification formation. Patients with frameshift and nonsense mutations had much more extensive SCOs than those with missense mutations. Males were affected more than females. There was no correlation with hormonal status or BMI.'
    explanation: The 67-person AHO cohort included 18 PPHP cases; ossification burden was similar between PPHP and PHP1A and did not correlate with BMI or hormone status.
- name: Osteoma cutis
  category: Dermatologic
  frequency: OCCASIONAL
  description: Cutaneous ossification can occur as an AHO-related soft-tissue manifestation.
  phenotype_term:
    preferred_term: Osteoma cutis
    term:
      id: HP:0025027
      label: Osteoma cutis
  evidence:
  - reference: ORPHA:79445
    supports: SUPPORT
    evidence_source: OTHER
    snippet: HP:0025027 | Osteoma cutis | Occasional (29-5%)
    explanation: Orphanet lists osteoma cutis as occasional in PPHP.
    reference_title: Pseudopseudohypoparathyroidism
- name: Obesity
  category: Metabolic
  frequency: OCCASIONAL
  description: >-
    Occasional obesity is reported by Orphanet. The severe early-onset obesity typical of maternal
    GNAS disease is usually absent; obesity alone does not establish misclassification or refute
    molecularly confirmed PPHP.
  phenotype_term:
    preferred_term: Obesity
    term:
      id: HP:0001513
      label: Obesity
  evidence:
  - reference: ORPHA:79445
    supports: SUPPORT
    evidence_source: OTHER
    snippet: HP:0001513 | Obesity | Occasional (29-5%)
    explanation: Orphanet lists obesity as occasional in PPHP.
    reference_title: Pseudopseudohypoparathyroidism
- name: Delayed speech and language development
  category: Neurological
  frequency: OCCASIONAL
  description: Speech and language delay is an occasional neurodevelopmental feature.
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: ORPHA:79445
    supports: SUPPORT
    evidence_source: OTHER
    snippet: HP:0000750 | Delayed speech and language development | Occasional (29-5%)
    explanation: Orphanet lists delayed speech and language development as occasional in PPHP.
    reference_title: Pseudopseudohypoparathyroidism
- name: Intellectual disability
  category: Neurological
  frequency: OCCASIONAL
  description: Intellectual disability is reported in a subset of PPHP cases.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: ORPHA:79445
    supports: SUPPORT
    evidence_source: OTHER
    snippet: HP:0001249 | Intellectual disability | Occasional (29-5%)
    explanation: Orphanet lists intellectual disability as occasional in PPHP.
    reference_title: Pseudopseudohypoparathyroidism
- name: Intrauterine growth retardation
  category: Growth
  frequency: OCCASIONAL
  description: Prenatal growth restriction is well documented in paternal GNAS disorders. Frequency estimates depend on cohort definition; mixed PPHP/POH birth-weight studies should not be treated as PPHP-only prevalence.
  phenotype_term:
    preferred_term: Intrauterine growth retardation
    term:
      id: HP:0001511
      label: Intrauterine growth retardation
  evidence:
  - reference: ORPHA:79445
    supports: SUPPORT
    evidence_source: OTHER
    snippet: HP:0001511 | Intrauterine growth retardation | Occasional (29-5%)
    explanation: Orphanet lists intrauterine growth retardation as occasional in PPHP.
    reference_title: Pseudopseudohypoparathyroidism
  - reference: PMID:23884777
    reference_title: Paternal GNAS mutations lead to severe intrauterine growth retardation (IUGR) and provide evidence for a role of XLαs in fetal development.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: birth weights were lower with paternal GNAS mutations affecting exons 2-13 than with exon 1/intron 1 mutations.
    explanation: Birth parameters from 26 PPHP/POH and 29 PHP-Ia patients support an exon-class association, not isolated proof that XL-alpha-s determines fetal growth.
biochemical:
- name: Parathyroid hormone resistance
  presence: Absent in classical PPHP
  context: >-
    Classical PPHP usually lacks PTH resistance. Rare phased paternal-variant cases with elevated
    PTH or blunted GH stimulation exist; this is an exception, not the defining biochemical pattern.
  evidence:
  - reference: ORPHA:79445
    supports: SUPPORT
    evidence_source: OTHER
    snippet: but no evidence of resistance to parathyroid hormone (PTH)
    explanation: Orphanet defines PPHP by AHO clinical features without evidence of PTH resistance.
    reference_title: Pseudopseudohypoparathyroidism
  - reference: PMID:25464124
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These findings suggest that PTH and other hormone resistance may not be an exclusive feature of PHP-Ia and could also be observed in patients with PPHP.
    explanation: This case report supports noting that hormone resistance can occasionally complicate the classical PPHP distinction.
    reference_title: Evidence of hormone resistance in a pseudo-pseudohypoparathyroidism patient with a novel paternal mutation in GNAS.
  - reference: PMID:34254228
    reference_title: Mild progressive osseous heteroplasia overlap syndrome with PTH and TSH resistance appearing during adolescence and not early childhood.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: he met the diagnostic criteria for POH, and mild PTH and TSH resistance was detected
    explanation: >-
      Adds a timing caveat to the biochemical pattern. In this case from the severe end of the
      GNAS-inactivation spectrum, pituitary stimulation was normal at 3 years and the TSH response
      was reduced at 13 years, so a normal childhood panel does not settle the question for life.
      The variant arose de novo and its parental allele was not determined, so the case does not
      itself demonstrate resistance with a phased paternal variant.
- name: Serum calcium
  presence: Normal
  context: Classical PPHP does not show the hypocalcemia typical of PTH resistance.
  evidence:
  - reference: ORPHA:79445
    supports: SUPPORT
    evidence_source: OTHER
    snippet: HP:0002901 | Hypocalcemia | Excluded (0%)
    explanation: Orphanet explicitly excludes hypocalcemia from the PPHP phenotype.
    reference_title: Pseudopseudohypoparathyroidism
- name: Serum phosphate
  presence: Normal
  context: Classical PPHP does not show the hyperphosphatemia typical of PTH resistance.
  evidence:
  - reference: ORPHA:79445
    supports: SUPPORT
    evidence_source: OTHER
    snippet: HP:0002905 | Hyperphosphatemia | Excluded (0%)
    explanation: Orphanet explicitly excludes hyperphosphatemia from the PPHP phenotype.
    reference_title: Pseudopseudohypoparathyroidism
- name: Circulating parathyroid hormone
  presence: Not elevated in classical PPHP
  context: PTH is normally not elevated in classical PPHP. An unexpected elevation requires assessment of calcium, phosphate, vitamin D, renal function and the molecular diagnosis.
  evidence:
  - reference: ORPHA:79445
    supports: SUPPORT
    evidence_source: OTHER
    snippet: HP:0003165 | Elevated circulating parathyroid hormone level | Excluded (0%)
    explanation: Orphanet explicitly excludes elevated circulating PTH from classical PPHP.
    reference_title: Pseudopseudohypoparathyroidism
genetic:
- name: GNAS
  gene_term:
    preferred_term: GNAS
    term:
      id: hgnc:4392
      label: GNAS
  association: Heterozygous GNAS coding loss of function on the paternal chromosome; inherited or de novo
  evidence:
  - reference: ORPHA:79445
    supports: SUPPORT
    evidence_source: OTHER
    snippet: GNAS | GNAS complex locus | hgnc:4392 | Disease-causing germline mutation(s) (loss of function) in
    explanation: Orphanet identifies GNAS loss-of-function germline mutations as disease-causing in PPHP.
    reference_title: Pseudopseudohypoparathyroidism
  - reference: PMID:15711092
    supports: SUPPORT
    evidence_source: OTHER
    snippet: PHP-Ia and PPHP are caused by heterozygous inactivating mutations in those exons of GNAS encoding the alpha subunit of the stimulatory guanine nucleotide-binding protein (Gsalpha)
    explanation: This supports heterozygous inactivating GNAS coding variants as causal for PPHP.
    reference_title: GNAS locus and pseudohypoparathyroidism.
  - reference: PMID:25802881
    reference_title: A positive genotype-phenotype correlation in a large cohort of patients with Pseudohypoparathyroidism Type Ia and Pseudo-pseudohypoparathyroidism and 33 newly identified mutations in the GNAS gene.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Comparing the clinical features to the molecular genetic data, a significantly higher occurrence of subcutaneous calcifications in patients harboring truncating versus missense mutations was demonstrated.
    explanation: >-
      The one reproducible genotype-phenotype correlation reported for this gene: the severity of
      the coding lesion tracks with ossification burden. The cohort pooled PHP1A and PPHP patients,
      so the correlation is a property of GNAS variant class rather than of PPHP specifically.
  - reference: PMID:36686455
    reference_title: Frequency of de novo variants and parental mosaicism in families with inactivating PTH/PTHrP signaling disorder type 2.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: De novo pathogenic variants are frequent in iPPSD2 (around 45%). Parental mosaicism is infrequent (8.11%) but should be analyzed with NGS, taking into account its importance in genetic counselling.
    explanation: >-
      Substantiates the inherited-or-de-novo part of this association. In a 95-proband series
      roughly half of cases were de novo, so an absent family history does not argue against the
      diagnosis, and parental mosaicism is rare but frequent enough to affect recurrence-risk
      counselling. The series is iPPSD2 as a whole rather than PPHP alone.
  inheritance:
  - name: Autosomal dominant
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
    expressivity: VARIABLE
    parent_of_origin_effect: "The sex of the transmitting parent determines the imprinted state in the next generation: paternal transmission generally produces PPHP/POH/osteoma cutis, whereas maternal transmission of a coding variant generally produces PHP1A, irrespective of the transmitting parent's own clinical phenotype."
    evidence:
    - reference: ORPHA:79445
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Autosomal dominant
      explanation: Orphanet reports autosomal dominant inheritance for PPHP.
      reference_title: Pseudopseudohypoparathyroidism
    - reference: PMID:40972900
      supports: SUPPORT
      evidence_source: OTHER
      snippet: While maternal mutations result in PHP type 1A, which consists of PTH resistance and AHO, paternal mutations lead to pseudo-pseudohypoparathyroidism (PPHP), that is, AHO without hormone resistance.
      explanation: This supports the parent-of-origin effect that determines the PPHP versus PHP1A phenotype.
      reference_title: 'Imprinting and skeletal disorders: lessons from pseudohypoparathyroidism and related disorders.'
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK459117/
      reference_title: Disorders of GNAS Inactivation - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: OTHER
      snippet: inactivation has a 50% chance of inheriting the parent's genetic alteration
      explanation: Autosomal dominant transmission risk must be coupled to parent-of-origin counselling.
  notes: Exon-1 variants primarily affect Gs-alpha, whereas shared-exon variants can affect additional transcripts including paternal XL-alpha-s. Receptor-specific mixed gain/loss-of-function variants can cause distinct SIADH/osteolysis phenotypes and require functional interpretation rather than automatic PPHP classification.
diagnosis:
- name: Clinical and biochemical recognition of AHO without PTH resistance
  description: >-
    Recognize the evolving AHO pattern using growth history, examination for superficial ossification,
    and hand/foot radiographs when useful. Obtain baseline calcium, phosphate, PTH, vitamin D
    and thyroid function to establish the endocrine phenotype and identify mimics. Routine PTH
    infusion testing is rarely required.
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: NCIT:C124351
      label: Clinical Evaluation
  results: AHO features with no classical PTH resistance.
  evidence:
  - reference: ORPHA:79445
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Pseudopseudohypoparathyroidism (pseudo-PHP) is a disease characterized by a constellation of clinical features collectively termed Albright hereditary osteodystrophy (AHO) but no evidence of resistance to parathyroid hormone (PTH), which is seen in other forms of pseudohypoparathyroidism (PHP).
    explanation: Orphanet defines the diagnostic distinction between PPHP and other PHP forms.
    reference_title: Pseudopseudohypoparathyroidism
  - reference: PMID:15711092
    supports: SUPPORT
    evidence_source: OTHER
    snippet: These features are also present in pseudopseudohypoparathyroidism (PPHP), but patients affected by this disorder do not show hormone resistance.
    explanation: This review supports assessing AHO features together with absent hormone resistance.
    reference_title: GNAS locus and pseudohypoparathyroidism.
  - reference: PMID:29959430
    reference_title: 'Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: At diagnosis or before initiation of treatment, we recommend the monitoring of serum levels of PTH, calcium, phosphorus and calcifediol.
    explanation: Baseline endocrine biochemistry establishes whether the classical PPHP pattern is present.
- name: GNAS molecular genetic testing
  description: >-
    Sequence GNAS coding exons and splice junctions and assess deletion/duplication when sequencing
    is unrevealing. Determine parental phase by family testing or informative molecular markers;
    a de novo variant may still be paternal. Methylation and imprinting-control testing are particularly
    relevant when the phenotype suggests PHP1B or coding testing is negative; an STX16 defect
    is not the usual cause of PPHP.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: NCIT:C19770
      label: Molecular Analysis
  results: Heterozygous GNAS loss-of-function variant, classically on the paternal allele.
  evidence:
  - reference: PMID:29959430
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The clinical and laboratory diagnosis should be confirmed by a molecular genetic analysis.
    explanation: Consensus guidance supports molecular genetic analysis to confirm PHP-related disorder diagnosis.
    reference_title: 'Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement.'
  - reference: ORPHA:79445
    supports: SUPPORT
    evidence_source: OTHER
    snippet: GNAS | GNAS complex locus | hgnc:4392 | Disease-causing germline mutation(s) (loss of function) in
    explanation: Orphanet identifies GNAS loss-of-function variants as the causal molecular finding.
    reference_title: Pseudopseudohypoparathyroidism
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK459117/
    reference_title: Disorders of GNAS Inactivation - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Sequence analysis of exons 1 through 13 of
    explanation: The testing sequence includes copy-number analysis rather than coding sequencing alone.
treatments:
- name: Individualized clinical surveillance with baseline endocrine assessment
  description: >-
    Assess growth, weight, puberty, thyroid function, new or enlarging ossifications, mobility,
    oral health and educational needs according to the phenotype. Establish calcium, phosphate,
    PTH and vitamin D status at diagnosis. Confirmed paternal GNAS cases do not require the routine
    serial PTH/calcium/phosphate testing schedule used for PHP1A; reassess when symptoms, abnormal
    results or uncertainty about parental phase warrant it. Treat documented hormone deficiencies,
    not the PPHP label alone.
  treatment_term:
    preferred_term: clinical assessment
    term:
      id: NCIT:C124351
      label: Clinical Evaluation
  target_phenotypes:
  - preferred_term: Ectopic ossification
    term:
      id: HP:0011986
      label: Ectopic ossification
  - preferred_term: Obesity
    term:
      id: HP:0001513
      label: Obesity
  - preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:29959430
    reference_title: 'Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: At diagnosis or before initiation of treatment, we recommend the monitoring of serum levels of PTH, calcium, phosphorus and calcifediol.
    explanation: Baseline endocrine biochemistry establishes whether the classical PPHP pattern is present.
  - reference: PMID:29959430
    reference_title: 'Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: exception of patients carrying either a GNAS muta- tion on the paternal allele or a PDE4D mutation in whom, apart from at diagnosis, routine assessment is not necessary.
    explanation: Recommendation 3.2 exempts paternal GNAS cases from routine repeated PTH/calcium/phosphate measurement after baseline. PDF line-break hyphenation is preserved in this exact excerpt.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK459117/
    reference_title: Disorders of GNAS Inactivation - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: New and/or enlarging ectopic ossifications;
    explanation: Clinical follow-up includes lesion progression.
- name: Coordinated multidisciplinary supportive management
  description: >-
    Management is coordinated across pediatric/adult endocrinology, genetics,
    orthopedics, dentistry, nutrition, and neurodevelopmental services according
    to the patient's manifestations.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_phenotypes:
  - preferred_term: Brachydactyly
    term:
      id: HP:0001156
      label: Brachydactyly
  - preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  - preferred_term: Ectopic ossification
    term:
      id: HP:0011986
      label: Ectopic ossification
  evidence:
  - reference: PMID:29959430
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Overall, a coordinated and multidisciplinary approach from infancy through adulthood, including a transition programme, should help us to improve the care of patients affected by these disorders.
    explanation: Consensus guidance supports multidisciplinary supportive management for PHP-related disorders including PPHP.
    reference_title: 'Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement.'
- name: Physical and occupational therapy with skin care
  description: Assess fine motor function and mobility, provide appropriate footwear or orthoses when needed, and maintain skin integrity over superficial ossifications. Tailor therapy to pain or functional limitation. Routine serial imaging of asymptomatic lesions is unnecessary; image painful, function-threatening or surgically considered lesions.
  evidence:
  - reference: PMID:29959430
    reference_title: 'Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: 'Physical therapy and meticulous skin care remain the most important conservative approaches to preserve movement and to prevent cutaneous breakdown, respectively251,252.'
    explanation: Consensus recommends physical therapy and skin care for ectopic ossification; the strength of evidence is limited.
  - reference: PMID:29959430
    reference_title: 'Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Regular imaging of ectopic ossifications is not indicated
    explanation: The consensus favors symptom-directed imaging.
  treatment_term:
    preferred_term: Physical therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
- name: Selective excision of symptomatic superficial ossifications
  description: An experienced surgeon may remove localized superficial lesions causing irritation, pain or impaired movement. Recurrence can occur. Deep progressive ossification needs specialist reassessment for POH overlap; surgery does not correct the underlying GNAS defect.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK459117/
    reference_title: Disorders of GNAS Inactivation - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Subcutaneous ossifications that are superficial and well circumscribed may be surgically removed when they are large or cause local irritation, although they may recur.
    explanation: Surgery is selective and recurrence is possible.
  treatment_term:
    preferred_term: Excision of superficial ossifications
    term:
      id: NCIT:C15232
      label: Excision
- name: Genetic counselling and family testing
  description: 'Each child of a heterozygous carrier has a 50% chance of inheriting the variant. The sex of the transmitting parent changes the expected phenotype in the child: paternal transmission usually causes PPHP/POH/osteoma cutis, whereas maternal transmission usually causes PHP1A. Establish phase and test relatives as appropriate; discuss variable expression, de novo or mosaic variants, and reproductive testing options.'
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK459117/
    reference_title: Disorders of GNAS Inactivation - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: inactivation has a 50% chance of inheriting the parent's genetic alteration
    explanation: GeneReviews supplies transmission risk; phenotype prediction also requires imprinting and parental origin.
  treatment_term:
    preferred_term: Genetic counselling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
notes: >-
  PPHP is a variable paternal GNAS phenotype, distinct from maternal-variant PHP1A and from deep
  progressive POH. AHO traits can emerge with age, and endocrine and neurocognitive findings require
  individual assessment. The international consensus exempts confirmed paternal GNAS cases from
  routine repeated PTH/calcium/phosphate measurement after baseline; repeat testing is appropriate
  for symptoms, abnormal baseline findings or uncertain molecular classification. Trial registration
  does not establish PPHP treatment efficacy.
differential_diagnoses:
- name: Pseudohypoparathyroidism type 1A
  description: Maternal coding GNAS variants can produce the same AHO skeletal findings.
  distinguishing_features:
  - PTH and other hormone resistance and severe early-onset obesity favor PHP1A; parental phase is decisive when findings overlap.
  evidence:
  - reference: PMID:16099856
    reference_title: A mouse model of albright hereditary osteodystrophy generated by targeted disruption of exon 1 of the Gnas gene.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Heterozygous mice that inherited the disruption maternally (-m/+) exhibited PTH and TSH resistance, whereas those with paternal inheritance (+/-p) had normal hormone responsiveness
    explanation: The exon-1 model supports the biological basis of the clinical distinction.
- name: Progressive osseous heteroplasia
  description: POH can result from paternal GNAS inactivation and share superficial ossifications with PPHP.
  distinguishing_features:
  - Progressive extension into deep fascia and skeletal muscle, often without the full AHO pattern, distinguishes POH. Overlap phenotypes occur, so it is not a predictable PPHP stage.
  evidence:
  - reference: PMID:33574833
    reference_title: Gnas Inactivation Alters Subcutaneous Tissues in Progression to Heterotopic Ossification.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: HO typically initiates within subcutaneous soft tissues before progressing to deeper connective tissues.
    explanation: The primary POH study defines the progressive lesion phenotype; it is not evidence that all PPHP progresses deeply.
- name: Acrodysostosis due to PRKAR1A or PDE4D
  description: Other cAMP/PKA-pathway disorders cause overlapping short stature and brachydactyly.
  distinguishing_features:
  - Diffuse early brachydactyly, nasal hypoplasia and advanced bone age suggest acrodysostosis; hormone resistance varies by genotype. PRKAR1A is iPPSD4 and PDE4D is iPPSD5.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK459117/
    reference_title: Disorders of GNAS Inactivation - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: is characterized by short stature, early-onset diffuse brachydactyly, round face, nasal hypoplasia, advanced bone age, and obesity.
    explanation: GeneReviews describes the distinguishing skeletal pattern.
  - reference: PMID:24363928
    reference_title: Acrodysostosis syndromes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Two different genetic and phenotypic syndromes are now identified, both with a similar bone dysplasia: ADOHR, due to PRKAR1A defects, and ADOP4 (our denomination), due to PDE4D defects. The existence of GPCR-hormone resistance is typical of the ADOHR syndrome."
    explanation: >-
      Separates the two acrodysostosis genes and names the hormone-resistance feature that
      distinguishes them from each other, which is the genotype dependence recorded in the
      distinguishing features above.
  - reference: PMID:27589370
    reference_title: 'Knock-In of the Recurrent R368X Mutation of PRKAR1A that Represses cAMP-Dependent Protein Kinase A Activation: A Model of Type 1 Acrodysostosis.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: This model, the first describing the germline expression of a PRKAR1A mutation causing dominant repression of cAMP-dependent PKA, reproduced the main features of ACRDYS1 in humans.
    explanation: >-
      Repressing PKA downstream of Gs-alpha reproduces the skeletal phenotype in mouse, which is
      why this differential is a cAMP-pathway phenocopy rather than a GNAS-specific finding.
- name: 2q37 deletion or HDAC4-related brachydactyly-intellectual disability syndrome
  description: AHO-like dysmorphism and developmental impairment can occur without GNAS disease.
  distinguishing_features:
  - Chromosomal or HDAC4 testing identifies a separate cause; the presence of developmental impairment and brachydactyly alone is insufficient for PPHP.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK459117/
    reference_title: Disorders of GNAS Inactivation - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: which is characterized by mild-moderate developmental delay/intellectual disability, brachydactyly of digits 3-5 (often digit 4 alone), short stature, obesity, hypotonia, round facies, behavioral abnormalities, joint hypermobility/dislocation, and scoliosis.
    explanation: The GeneReviews differential includes 2q37 deletion and HDAC4-related AHO-like disease.
- name: Isolated brachydactyly type E
  description: HOXD13 or PTHLH variants can produce shortened metacarpals and metatarsals.
  distinguishing_features:
  - Ectopic ossification and intellectual disability are generally absent in the isolated phenotype; molecular testing distinguishes these pathway-related conditions.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK459117/
    reference_title: Disorders of GNAS Inactivation - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Some individuals have moderate short stature and round facies but do not have ectopic ossification or intellectual disability.
    explanation: The isolated brachydactyly differential lacks key extraskeletal features.
  - reference: PMID:34897794
    reference_title: Novel Pathogenetic Variants in PTHLH and TRPS1 Genes Causing Syndromic Brachydactyly.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Unfortunately, we could not find distinctive phenotypic features that might have led to an earlier clinical diagnosis, further highlighting the high degree of overlap among skeletal syndromes associated with brachydactyly and AHO-like features
    explanation: >-
      Five patients with an AHO-like skeletal phenotype turned out to carry PTHLH or TRPS1 variants,
      and the authors found no clinical feature that would have separated them beforehand. This is
      the reason molecular testing, not the skeletal pattern, is recorded as the discriminator.
      TRPS1 disease is not curated as a separate differential here; it adds sparse hair, a
      pear-shaped nose, and cone-shaped epiphyses.
discussions:
- discussion_id: gnas_mixed_function_variant_scope
  prompt: >-
    Should GNAS missense variants with mixed receptor-specific gain- and loss-of-function
    behaviour be curated inside the PPHP parent-of-origin model, or as a separate entity?
  kind: OPEN_QUESTION
  status: OPEN
  attaches_to:
  - mechanistic_hypotheses#pphp_parent_of_origin_model
  - genetic#GNAS
  rationale: >-
    A small number of germline GNAS missense variants act as constitutive, ligand-independent
    activators at one receptor while blunting ligand-dependent signaling at another. Carriers
    present with nephrogenic syndrome of inappropriate antidiuresis, precocious puberty, or
    osteolytic metaphyseal bone disease rather than with AHO, and at least two reported variants
    sat on the paternal allele. These are not counterexamples to the parent-of-origin model,
    which is stated for coding loss-of-function variants, but they do mean a paternal GNAS
    missense finding cannot be assumed loss-of-function from its position alone. The practical
    question for this entry is whether the scope sentence already carried in the genetic notes is
    enough, or whether the mixed-function phenotypes need their own entry; the frequency of such
    variants among GNAS missense findings has never been measured, which is what makes the
    question hard to settle.
  evidence:
  - reference: PMID:30312418
    reference_title: A New Multisystem Disorder Caused by the Gαs Mutation p.F376V.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: In vitro studies demonstrated that Gαs-F376V enhanced ligand-independent signaling at the PTH1R, LHCGR, and V2R and, at the same time, blunted ligand-dependent responses.
    explanation: >-
      The original demonstration that one GNAS missense variant can be activating and inactivating
      at once, depending on receptor and on whether ligand is present. This variant was maternal,
      so it establishes the phenomenon rather than the paternal-allele case.
  - reference: PMID:40172207
    reference_title: Germline-derived GNAS-Gsα variants associated with both gain-of-function and loss-of-function phenotypes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: One of the mothers, with the variant in her paternal allele, presented NSIAD.
    explanation: >-
      Places a mixed-function variant on the paternal allele in a carrier who presented with
      inappropriate antidiuresis rather than with AHO, which is the observation that makes this a
      scope question for the PPHP model.
  - reference: PMID:41530545
    reference_title: De novo GNAS-Gsα variant (p.Thr55Ala) with constitutive gain-of-function effects on AVPR2 and PTH1R signalings.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Luciferase assays for p.Thr55Ala showed ligand-independent GOF effects on AVPR2 and PTH1R signalings, and a ligand-dependent loss-of-function (LOF) effect on PTH1R signaling.
    explanation: >-
      A second variant with the same dual behaviour, assayed receptor by receptor. It arose de novo
      on the paternally inherited allele in a patient with inappropriate antidiuresis and
      osteolytic metaphyseal bone disease rather than AHO, which is the genotype-to-allele
      combination a paternal-variant model would otherwise be read as predicting.
progression:
- phase: Prenatal and childhood growth abnormalities
  notes: Intrauterine growth restriction can precede recognizable AHO. Brachydactyly and short stature evolve with skeletal maturation rather than necessarily being complete at birth.
  evidence:
  - reference: PMID:23884777
    reference_title: Paternal GNAS mutations lead to severe intrauterine growth retardation (IUGR) and provide evidence for a role of XLαs in fetal development.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Heterozygous GNAS mutations on either parental allele were associated with IUGR.
    explanation: The birth-parameter cohort documents prenatal involvement.
- phase: Variable lifelong superficial ossification burden
  notes: Superficial ossification burden can increase with age, with substantial variability within and between families. Deep progressive extension indicates a POH or overlap phenotype and is not an obligatory PPHP trajectory.
  evidence:
  - reference: PMID:29059381
    reference_title: 'Ossifications in Albright Hereditary Osteodystrophy: Role of Genotype, Inheritance, Sex, Age, Hormonal Status, and BMI.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Males are affected more extensively than females, and the SCOs tend to worsen with age.
    explanation: Longitudinal clinical assessment supports age-related lesion burden.
animal_models:
- name: Parent-specific heterozygous Gnas exon-1 mouse
  species: Mouse
  genotype: GnasE1+/- with maternal or paternal inheritance
  description: Exon-1 disruption separates Gs-alpha from other locus transcripts. Both parental forms develop superficial ossifications, while endocrine and metabolic phenotypes depend on parental origin. Later bone-remodeling differences were predominantly female and should not be converted into an established human PPHP osteoporosis phenotype.
  modeled_mechanisms:
  - target: Reduced Gs-alpha dosage in biallelic tissues
    relationship: PARTIALLY_RECAPITULATES
    description: Exon-1 heterozygosity models partial Gs-alpha loss; expression studies identify biallelic tissues.
    limitations: Species, zygosity and tissue context limit direct extrapolation to human heterozygous PPHP.
    evidence:
    - reference: PMID:16099856
      reference_title: A mouse model of albright hereditary osteodystrophy generated by targeted disruption of exon 1 of the Gnas gene.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Galphas protein and mRNA expression was consistent with paternal imprinting in the renal cortex and thyroid, but there was no imprinting in renal medulla, heart, or adipose.
      explanation: The exon-1 study directly evaluates tissue-specific Gs-alpha expression in the described model; the separate exon-2 chimera is not used as its experimental provenance.
  - target: Dermal and subcutaneous ectopic bone formation
    relationship: PARTIALLY_RECAPITULATES
    description: Both parental forms develop AHO-like ectopic bone.
    limitations: Species, zygosity and tissue context limit direct extrapolation to human heterozygous PPHP.
    evidence:
    - reference: PMID:21747923
      reference_title: Heterotopic ossifications in a mouse model of albright hereditary osteodystrophy.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Gnas(E1-/+) mice develop SCO features that are similar to those observed in AHO patients
      explanation: Heterozygous Gnas exon-1 mice reproduce superficial ectopic bone.
  evidence:
  - reference: PMID:35079678
    reference_title: Parental Origin of Gsα Inactivation Differentially Affects Bone Remodeling in a Mouse Model of Albright Hereditary Osteodystrophy.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: GnasE1+/-p mice exhibited reduced bone parameters due to impaired bone formation and enhanced bone resorption.
    explanation: Predominantly female mouse effects show that a universal complete-knockout bone model is inadequate.
  - reference: PMID:21747923
    reference_title: Heterotopic ossifications in a mouse model of albright hereditary osteodystrophy.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Gnas(E1-/+) mice develop SCO features that are similar to those observed in AHO patients
    explanation: Heterozygous Gnas exon-1 mice reproduce superficial ectopic bone.
- name: Heterozygous chondrocyte chimera
  species: Mouse
  genotype: Chimeric wild-type and Gnas+/E2- growth plates
  description: Approximately half-normal Gs-alpha RNA after either parental disruption is accompanied by modest premature hypertrophy. The design does not reproduce human digit-selective brachydactyly.
  modeled_mechanisms:
  - target: Premature chondrocyte hypertrophy
    relationship: PARTIALLY_RECAPITULATES
    description: A dosage-relevant cellular phenotype supports the growth-plate mechanism.
    limitations: Species, zygosity and tissue context limit direct extrapolation to human heterozygous PPHP.
    evidence:
    - reference: PMID:15459318
      reference_title: Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Hypertrophy of Gnas(+/E2-) chondrocytes was modestly but significantly premature in chimeric growth plates of mice containing wild-type and Gnas(+/E2-) cells.
      explanation: The heterozygous chimera shows modest premature hypertrophy; it does not establish human digit selectivity.
  evidence:
  - reference: PMID:15459318
    reference_title: Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Hypertrophy of Gnas(+/E2-) chondrocytes was modestly but significantly premature in chimeric growth plates of mice containing wild-type and Gnas(+/E2-) cells.
    explanation: The heterozygous chimera shows modest premature hypertrophy; it does not establish human digit selectivity.
- name: Complete and partial chondrocyte-specific Gnas deletion
  species: Mouse
  genotype: Col2a1-Cre; Gnas floxed null or heterozygous
  description: Complete deletion causes severe growth-plate defects and perinatal death; heterozygotes in the same study have no overt phenotype. These are pathway-necessity and negative dosage observations, respectively.
  modeled_mechanisms:
  - target: Reduced PTHrP-dependent chondrocyte signaling
    relationship: PERTURBS
    description: Complete deletion perturbs the PTHrP/Gs-alpha pathway.
    limitations: Species, zygosity and tissue context limit direct extrapolation to human heterozygous PPHP.
    evidence:
    - reference: PMID:15765186
      reference_title: Chondrocyte-specific knockout of the G protein G(s)alpha leads to epiphyseal and growth plate abnormalities and ectopic chondrocyte formation.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Mice with complete chondrocyte-specific G(s)alpha deficiency (homozygotes) died within minutes after birth and had severe epiphyseal and growth plate defects with shortening of the proliferative zone and accelerated hypertrophic differentiation of growth plate chondrocytes, a phenotype similar to that of PTH/PTH-related peptide (PTHrP) receptor knockout mice.
      explanation: Complete conditional knockout establishes pathway necessity, whereas heterozygotes in this separate model had no overt phenotype.
  - target: Premature chondrocyte hypertrophy
    relationship: FAILS_TO_RECAPITULATE
    description: Partial deletion in this model does not reproduce the overt skeletal phenotype.
    limitations: Species, zygosity and tissue context limit direct extrapolation to human heterozygous PPHP.
    evidence:
    - reference: PMID:15765186
      reference_title: Chondrocyte-specific knockout of the G protein G(s)alpha leads to epiphyseal and growth plate abnormalities and ectopic chondrocyte formation.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Mice with partial G(s)alpha deficiency (heterozygotes) exhibited no phenotype.
      explanation: Complete conditional knockout establishes pathway necessity, whereas heterozygotes in this separate model had no overt phenotype.
  evidence:
  - reference: PMID:15765186
    reference_title: Chondrocyte-specific knockout of the G protein G(s)alpha leads to epiphyseal and growth plate abnormalities and ectopic chondrocyte formation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Mice with complete chondrocyte-specific G(s)alpha deficiency (homozygotes) died within minutes after birth and had severe epiphyseal and growth plate defects with shortening of the proliferative zone and accelerated hypertrophic differentiation of growth plate chondrocytes, a phenotype similar to that of PTH/PTH-related peptide (PTHrP) receptor knockout mice.
    explanation: Complete conditional knockout establishes pathway necessity, whereas heterozygotes in this separate model had no overt phenotype.
- name: AHO alpha-SMA lineage tracing and Sfrp2 modifier mouse
  species: Mouse
  genotype: GnasE1+/-; alphaSMACreERT2; Ai9, with or without Sfrp2 deletion
  description: Alpha-SMA-labelled cells contribute to ossifications after long-term tracing; initial labels include dermal sheath, arrector pili and vessels. Sfrp2 deletion accelerates lesions in male AHO mice, with no corresponding significant female effect. Fate mapping does not prove selective lineage necessity or human cell identity.
  modeled_mechanisms:
  - target: Dermal and subcutaneous ectopic bone formation
    relationship: PARTIALLY_RECAPITULATES
    description: Lineage tracing identifies contributing cells and modifier perturbation changes lesion burden.
    limitations: Species, zygosity and tissue context limit direct extrapolation to human heterozygous PPHP.
    evidence:
    - reference: PMID:40256763
      reference_title: Alpha-smooth muscle actin-expressing dermal sheath cells are a major cellular contributor to heterotopic subcutaneous ossifications in a mouse model of Albright hereditary osteodystrophy.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Here we show that SCO formation occurs due to inappropriate expansion and osteogenic differentiation of cells that express alpha-smooth muscle actin and that are located within the dermal sheath.
      explanation: Mouse alpha-SMA fate mapping supports a dermal-sheath contribution; initial labeling includes additional alpha-SMA populations and does not establish human cell identity.
    - reference: PMID:40256763
      reference_title: Alpha-smooth muscle actin-expressing dermal sheath cells are a major cellular contributor to heterotopic subcutaneous ossifications in a mouse model of Albright hereditary osteodystrophy.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: elimination of Sfrp2 in male AHO mice leads to earlier development, greater severity, and acceleration of formation of SCOs.
      explanation: Sfrp2 deletion worsens lesions in male AHO mice, supporting a protective modifier rather than an obligatory pathogenic SFRP2 increase.
  evidence:
  - reference: PMID:40256763
    reference_title: Alpha-smooth muscle actin-expressing dermal sheath cells are a major cellular contributor to heterotopic subcutaneous ossifications in a mouse model of Albright hereditary osteodystrophy.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Here we show that SCO formation occurs due to inappropriate expansion and osteogenic differentiation of cells that express alpha-smooth muscle actin and that are located within the dermal sheath.
    explanation: Mouse alpha-SMA fate mapping supports a dermal-sheath contribution; initial labeling includes additional alpha-SMA populations and does not establish human cell identity.
  - &id002
    reference: PMID:40256763
    reference_title: Alpha-smooth muscle actin-expressing dermal sheath cells are a major cellular contributor to heterotopic subcutaneous ossifications in a mouse model of Albright hereditary osteodystrophy.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: elimination of Sfrp2 in male AHO mice leads to earlier development, greater severity, and acceleration of formation of SCOs.
    explanation: Sfrp2 deletion worsens lesions in male AHO mice, supporting a protective modifier rather than an obligatory pathogenic SFRP2 increase.
- name: Conditional Gnas-null POH models
  species: Mouse
  genotype: Conditional Gnas-null mesenchymal cells and host tissues
  description: Related POH models support Hedgehog activation, YAP-SHH paracrine recruitment and effects of the mutant host environment on wild-type cells. Null dosage and deep progressive disease limit transfer to heterozygous superficial PPHP.
  modeled_mechanisms:
  - target: Hedgehog-dependent osteogenic activation
    relationship: PARTIALLY_RECAPITULATES
    description: Hedgehog perturbation affects ectopic osteogenesis.
    limitations: Species, zygosity and tissue context limit direct extrapolation to human heterozygous PPHP.
    evidence:
    - reference: PMID:24076664
      reference_title: Activation of Hedgehog signaling by loss of GNAS causes heterotopic ossification.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Here we demonstrate that Gαs restricts bone formation to the skeleton by inhibiting Hedgehog signaling in mesenchymal progenitor cells.
      explanation: Perturbation studies support a Hedgehog-dependent mechanism in Gnas-null POH models; direct transfer to heterozygous human PPHP remains provisional.
  - target: YAP-SHH paracrine recruitment
    relationship: PARTIALLY_RECAPITULATES
    description: Cell and host manipulations interrogate paracrine propagation.
    limitations: Species, zygosity and tissue context limit direct extrapolation to human heterozygous PPHP.
    evidence:
    - reference: PMID:34162750
      reference_title: A self-amplifying loop of YAP and SHH drives formation and expansion of heterotopic ossification.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: We further showed that loss of Gnas led to activation of YAP transcription activity, which directly drove Shh expression.
      explanation: Gnas-null mesenchymal cells support YAP-SHH-mediated propagation; the model is not equivalent to heterozygous PPHP.
    - reference: PMID:33574833
      reference_title: Gnas Inactivation Alters Subcutaneous Tissues in Progression to Heterotopic Ossification.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: We found that mutant cells in a Gnas-null tissue environment induced a robust HO response while little/no HO was detected in control hosts.
      explanation: Mutant-host transplantation experiments support a permissive non-cell-autonomous environment in a POH model.
  evidence:
  - reference: PMID:24076664
    reference_title: Activation of Hedgehog signaling by loss of GNAS causes heterotopic ossification.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Here we demonstrate that Gαs restricts bone formation to the skeleton by inhibiting Hedgehog signaling in mesenchymal progenitor cells.
    explanation: Perturbation studies support a Hedgehog-dependent mechanism in Gnas-null POH models; direct transfer to heterozygous human PPHP remains provisional.
  - reference: PMID:34162750
    reference_title: A self-amplifying loop of YAP and SHH drives formation and expansion of heterotopic ossification.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We further showed that loss of Gnas led to activation of YAP transcription activity, which directly drove Shh expression.
    explanation: Gnas-null mesenchymal cells support YAP-SHH-mediated propagation; the model is not equivalent to heterozygous PPHP.
  - reference: PMID:33574833
    reference_title: Gnas Inactivation Alters Subcutaneous Tissues in Progression to Heterotopic Ossification.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We found that mutant cells in a Gnas-null tissue environment induced a robust HO response while little/no HO was detected in control hosts.
    explanation: Mutant-host transplantation experiments support a permissive non-cell-autonomous environment in a POH model.
experimental_models:
- name: Patient-derived dermal fibroblast microarrays
  experimental_model_type: PRIMARY_CELL_CULTURE
  cell_source: Dermal fibroblast cultures from three PPHP, one PHP1A and one POH participant
  description: Affymetrix U133 Plus 2.0 comparisons across five participants identified 23 shared differentially expressed genes, including SFRP2. P2 contributes to two contrasts and is the mother of P3; age, sex, subtype, relatedness and lesion burden can confound expression. This is patient-cell omics, but not fresh-lesion single-cell lineage proof. No raw accession was identified in the inspected paper.
  modeled_mechanisms:
  - target: Dermal and subcutaneous ectopic bone formation
    relationship: MEASURES
    description: Expression correlates with lesion burden but does not isolate causal human progenitors.
    limitations: Cultured dermal fibroblasts may differ from fresh lesion progenitors. The five-person comparisons mix PPHP, PHP1A and POH and are confounded by age, sex, relatedness, lesion burden and repeated use of one participant.
    evidence:
    - reference: PMID:40256763
      reference_title: Alpha-smooth muscle actin-expressing dermal sheath cells are a major cellular contributor to heterotopic subcutaneous ossifications in a mouse model of Albright hereditary osteodystrophy.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: In all 3 comparisons (P1 × P2, P3 × P2, and P4 × P5), a participant with the greater number (and size as well) of SCOs was compared to a participant with fewer or no ossifications.
      explanation: Cultured fibroblast microarrays include three PPHP participants, one PHP1A participant and one POH participant. Comparisons are small, heterogeneous and partly related, not independent patient-level replication.
  evidence:
  - &id003
    reference: PMID:40256763
    reference_title: Alpha-smooth muscle actin-expressing dermal sheath cells are a major cellular contributor to heterotopic subcutaneous ossifications in a mouse model of Albright hereditary osteodystrophy.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: In all 3 comparisons (P1 × P2, P3 × P2, and P4 × P5), a participant with the greater number (and size as well) of SCOs was compared to a participant with fewer or no ossifications.
    explanation: Cultured fibroblast microarrays include three PPHP participants, one PHP1A participant and one POH participant. Comparisons are small, heterogeneous and partly related, not independent patient-level replication.
clinical_trials:
- name: NCT00209235
  phase: NOT_APPLICABLE
  status: ACTIVE_NOT_RECRUITING
  description: AHO natural-history and cognitive/behavioral follow-up explicitly includes mutation-confirmed PPHP. The growth-hormone substudy is restricted to PHP1A and must not be interpreted as PPHP efficacy evidence.
  notes: ClinicalTrials.gov API checked 2026-09-04. Previously enrolled participants only; PPHP natural-history ages 0.2–89 years and cognitive ages 4–65 years. Registration does not establish a large independent PPHP cohort.
  evidence:
  - reference: clinicaltrials:NCT00209235
    reference_title: 'Natural History Study of Albright Hereditary Osteodystrophy: Includes Substudies on Effects of Growth Hormone in Patients With Pseudohypoparathyroidism Type 1A and Cognitive & Behavioral Studies in Albright Hereditary Osteodystrophy'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We, the researchers, are following the natural history of Albright hereditary osteodystrophy.
    explanation: The registry establishes ongoing natural-history research; API eligibility separates PPHP follow-up from the PHP1A GH arm.
- name: NCT03761290
  phase: NOT_APPLICABLE
  status: TERMINATED
  description: Observational glucose-homeostasis study enrolling PHP1A/PPHP participants and matched controls. The record reports 14 participants and termination because COVID precautions prevented healthy-control enrollment and funding ended.
  notes: API checked 2026-09-04. The registered design and incomplete enrollment do not establish PPHP diabetes risk or a therapeutic effect.
  evidence:
  - reference: clinicaltrials:NCT03761290
    reference_title: Glucose Homeostasis and Beta Cell Function in Pseudohypoparathyroidism
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In this pilot study we will assess β-cell function in patients with PHP1A and pseudopseudohypoparathyroidism PPHP.
    explanation: The protocol explicitly includes PPHP.
- name: NCT00001242
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: Historical NIH study of vitamin D/PTH resistance and related disorders; eligibility explicitly includes PPHP or suspected PPHP. Its diagnostic evaluation and inclusion in other protocols are not a PPHP-specific intervention result.
  notes: API eligibility and completed status checked 2026-09-04.
  evidence:
  - reference: clinicaltrials:NCT00001242
    reference_title: Studies of States With Resistance to Vitamin D and Parathyroid Hormone
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients will be tested with multiple indices of mineral metabolism to establish the diagnosis and examine the spectrum of the underlying disorder.
    explanation: The registry describes diagnostic characterization of related mineral-metabolism conditions.
- name: NCT04551170
  phase: PHASE_II
  status: ACTIVE_NOT_RECRUITING
  description: Related PHP/AHO trial of the PDE inhibitor theophylline in children aged 2–12 years, with obesity required. The protocol targets cAMP signaling, BMI and epiphyseal closure. Broad clinical criteria do not establish a molecular PPHP subgroup or PPHP skeletal efficacy.
  notes: API checked 2026-09-04. This record contradicts a blanket absence of pathway-directed AHO trials; theophylline remains investigational and is not presented as established PPHP treatment.
  evidence:
  - reference: clinicaltrials:NCT04551170
    reference_title: Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This phase 2 clinical trial and open-label extension study will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism.
    explanation: A registered cAMP-pathway trial exists in the related PHP/AHO population.
references:
- reference: url:https://www.ncbi.nlm.nih.gov/books/NBK459117/
  title: Disorders of GNAS Inactivation - GeneReviews® - NCBI Bookshelf
  tags:
  - GeneReviews
  findings:
  - statement: Clinical, molecular, differential-diagnosis and counselling framework for GNAS inactivation disorders; PHP1A frequencies and treatment evidence must not be assigned to PPHP. The 2018 consensus supplies a more specific PPHP exception to routine mineral biochemistry.
- reference: PMID:40256763
  title: Alpha-smooth muscle actin-expressing dermal sheath cells are a major cellular contributor to heterotopic subcutaneous ossifications in a mouse model of Albright hereditary osteodystrophy.
  findings:
  - statement: Mouse alpha-SMA lineage tracing supports a dermal-sheath contribution, and Sfrp2 deletion worsens male AHO ossification. Human mixed-subtype fibroblast microarrays provide limited omics evidence; neither the human cell of origin nor efficacy of SFRP2 treatment is established.
    evidence:
    - *id002
    - *id003
📚

References & Deep Research

References

2
url:https://www.ncbi.nlm.nih.gov/books/NBK459117/
Disorders of GNAS Inactivation - GeneReviews® - NCBI Bookshelf
1 finding
Clinical, molecular, differential-diagnosis and counselling framework for GNAS inactivation disorders; PHP1A frequencies and treatment evidence must not be assigned to PPHP. The 2018 consensus supplies a more specific PPHP exception to routine mineral biochemistry.
PMID:40256763
Alpha-smooth muscle actin-expressing dermal sheath cells are a major cellular contributor to heterotopic subcutaneous ossifications in a mouse model of Albright hereditary osteodystrophy.
1 finding
Mouse alpha-SMA lineage tracing supports a dermal-sheath contribution, and Sfrp2 deletion worsens male AHO ossification. Human mixed-subtype fibroblast microarrays provide limited omics evidence; neither the human cell of origin nor efficacy of SFRP2 treatment is established.
Show evidence (2 references)
PMID:40256763 SUPPORT Model Organism
"elimination of Sfrp2 in male AHO mice leads to earlier development, greater severity, and acceleration of formation of SCOs."
Sfrp2 deletion worsens lesions in male AHO mice, supporting a protective modifier rather than an obligatory pathogenic SFRP2 increase.
+ 1 more reference

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Asta ▸
Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Pseudopseudohypoparathyroidism. Core disease mechanisms, molecular and cel...
Asta Scientific Corpus Retrieval 20 citations 2026-05-10T11:15:16.386098

Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Pseudopseudohypoparathyroidism. Core disease mechanisms, molecular and cel...

This report is retrieval-only and is generated directly from Asta results.

  • Papers retrieved: 20
  • Snippets retrieved: 20

Relevant Papers

[1] Changes in Serum Proteomic Profiles at Different Stages of Pregnancy Toxemia in Goats

  • Authors: M. Uzti̇mür, C. N. Ünal, Gurler Akpinar
  • Year: 2025
  • Venue: Journal of Veterinary Internal Medicine
  • URL: https://www.semanticscholar.org/paper/4b9c488b5dbd65d7b26fd2ad9aed70e8c4b59942
  • DOI: 10.1111/jvim.70139
  • PMID: 40492724
  • PMCID: 12150350
  • Summary: Understanding the serum proteome profiles of goats with pregnancy toxemia might help identify the proteomes and pathways responsible for the development of this disease and improve diagnosis and treatment.
  • Evidence snippets:
  • Snippet 1 (score: 0.412) > The pathophysiology and progression of this disease are not fully understood. > Traditional biomedical research has focused on the analysis of single genes, proteins, metabolites, or metabolic pathways in diseases. This molecular reductionist approach is based on the assumption that identifying genetic variations and molecular components will lead to new treatments for diseases [13][14][15][16]. However, many diseases are complex and multifactorial, and in order to determine the phenotype of such diseases, it is necessary to understand the changes that occur in more than one gene, pathway, protein, or metabolite at the cellular, tissue, and organismal levels [17][18][19]. Therefore, in recent years, proteomics, as one field of multi-omics technologies, has helped in evaluating the complex pathogenetic mechanisms of different diseases from a broad perspective and has made substantial contributions [20,21]. In veterinary medicine, proteomic analysis of metabolic diseases such as ketosis [16], hypocalcemia [22], and fatty liver [23] in dairy cows has contributed valuable insights for the definition of new pathophysiological pathways and new diagnosis and treatment protocols for these diseases. The proteomic approach can contribute importantly to a broad and detailed understanding of the changes that occur at the organismal level associated with the increase in BHBA concentration in goats with pregnancy toxemia. Our aim was to evaluate the serum protein profiles of goats with SPT or CPT using proteomic techniques to determine the proteomic profiles of these animals and to identify the relevant pathophysiological mechanisms.

[2] Organoids in gastrointestinal diseases: from bench to clinic

  • Authors: Qinying Wang, Fanying Guo, Qinyuan Zhang, Tingting Hu, Yutao Jin et al.
  • Year: 2024
  • Venue: MedComm
  • URL: https://www.semanticscholar.org/paper/9b8880d8b9d45670da950197d7e353794f51d09e
  • DOI: 10.1002/mco2.574
  • PMID: 38948115
  • PMCID: 11214594
  • Citations: 12
  • Summary: A comprehensive and systematical depiction of organoids models is drawn, providing a novel insight into the utilization of organoids models from bench to clinic and clinical adhibition.
  • Evidence snippets:
  • Snippet 1 (score: 0.409) > Organoids models offer a robust platform for investigating the potential mechanisms of GI diseases and evaluating potential therapeutic interventions.By culturing organoids derived from patients' tissues or stem cells, researchers can delve into disease-specific cellular and molecular pathways, encompassing aberrant cell signaling, perturbed immune responses, and dysfunctional metabolic processes.These disease-specific phenotypes enable the study of disease progression, screening of prospective therapeutics, as well as identification of novel drug targets and mechanisms of action for GI diseases in a clinically relevant context.

[3] Clinical Presentation of Hypoparathyroidism

  • Authors: C. Cipriani, J. Bilezikian
  • Year: 2021
  • Venue: Journal of the Endocrine Society
  • URL: https://www.semanticscholar.org/paper/2f0655faa0e9d3d8649ce770c4f092c4a8ae5705
  • DOI: 10.1210/jendso/bvab003
  • PMID: 33542968
  • PMCID: 7846073
  • Citations: 9
  • Summary: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercialNoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.
  • Evidence snippets:
  • Snippet 1 (score: 0.402) > Hypoparathyroidism is a rare endocrine disorder whose clinical manifestations and complications involve the perturbation of several organs and systems that are specifically related to the target organs of parathyroid hormone (PTH). Chronic hypoparathyroidism is characterized by hypocalcemia and deficient PTH secretion. Levels are usually below detection limits of clinical assays for PTH. Hypoparathyroidism occurs most often as a complication of anterior neck surgery but can also occur as a genetic, autoimmune, or idiopathic disorder. > Hypocalcemia, hyperphosphatemia, and low or undetectable PTH levels are the hallmark laboratory findings in hypoparathyroidism; hypercalciuria may be present, as well. The clinical presentation of hypoparathyroidism is characterized not only by these biochemical abnormalities but also by a wide range of complications that relate specifically to the chronic effects of these metabolic abnormalities on different organs [1][2][3]. The neuromuscular and cardiovascular systems may be involved, with effects ranging from acute, life threatening manifestations (eg, tetany, seizures, arrhythmias) to long-term complications (eg, cerebral, vascular, renal or other ectopic calcifications) [2]. The organs that can be affected include, but are not limited to, the skeleton, kidneys, skin, and gastrointestinal, ocular, and dental systems [2,3]. Related to many of these complications or perhaps as a separate entity, quality of life is typically adversely impacted [4]. > In the last decade, several studies have focused on the prevalence, natural history, and pathophysiology of hypoparathyroidism and its complications. This research has offered new insights into a disease with protean manifestations [3]. Moreover, and similar to primary hyperparathyroidism [5], published observations from different geographical areas gain an advantage by comparing and contrasting the clinical profiles of hypoparathyroidism as they present around the world.

[4] New therapeutic targets in rare genetic skeletal diseases

  • Authors: M. Briggs, Peter A. Bell, M. Wright, K. A. Pirog
  • Year: 2015
  • Venue: Expert Opinion on Orphan Drugs
  • URL: https://www.semanticscholar.org/paper/1363107f71ae6d2d60abca471cddf3da5d13644b
  • DOI: 10.1517/21678707.2015.1083853
  • PMID: 26635999
  • PMCID: 4643203
  • Citations: 38
  • Influential citations: 1
  • Summary: An overview of disease mechanisms that are shared amongst groups of different GSDs and potential therapeutic approaches that are under investigation are described to generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.
  • Evidence snippets:
  • Snippet 1 (score: 0.396) > proteins of the cartilage ECM such as type II collagen [50]. However, emerging knowledge suggests that the primary genetic defect may be less important than the cells' response to the expression of the mutant gene product [107]. Moreover, the largely overlooked response of a cell (i.e. chondrocyte) to the abnormal extracellular environment is also important for disease progression as illustrated by several GSDs discussed in this review. > It is important that 'omics'-based approaches and technologies are systematically applied to the study of rare GSDs so that definitive reference profiles and disease signatures are generated for each phenotype. These can then be used in a Systems Biology approach to identify both common and dissimilar pathological signatures and disease mechanisms. This approach is entirely dependent upon relevant in vitro and in vivo models (and also novel 'disease-mechanism phenocopies' [107]) for testing new diagnostic and prognostic tools and for determining the molecular mechanisms that underpin the pathophysiology so that effective therapeutic treatments can be developed and validated. This approach will eventually lead to personalized treatments and care strategies centred on shared disease mechanisms with the use of relevant biomarkers to monitor the efficacy of treatment and disease progression. > It is vital that all relevant stakeholders are involved from the outset in defining the appropriate outcomes of any potential therapeutic regime. The perceptions of a successful therapy can differ widely between the clinical academic community and the relevant patient-support groups and it is vital that there is engagement on all these issues. > In summary, the identification of causative genes and mutations for GSDs over the last 20 years, coupled with the generation and in-depth analysis of a plethora of relevant cell and mouse models, has derived new knowledge on disease mechanisms and suggested potential therapeutic targets. The fast-evolving hypothesis that clinically disparate diseases can share common disease mechanisms is a powerful concept that will generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.

[5] Homocysteine thiolactone and N-homocysteinylated protein induce pro-atherogenic changes in gene expression in human vascular endothelial cells

  • Authors: D. Gurda, L. Handschuh, Weronika Kotkowiak, H. Jakubowski
  • Year: 2015
  • Venue: Amino Acids
  • URL: https://www.semanticscholar.org/paper/0e9ac31119ab67e72fdaa6e9cc442fa7ed2f4642
  • DOI: 10.1007/s00726-015-1956-7
  • PMID: 25802182
  • PMCID: 4458266
  • Citations: 93
  • Influential citations: 3
  • Summary: It is found that each Hcy metabolite uniquely modulates gene expression in pathways important for vascular homeostasis and identify new genes and pathways that are linked to HHcy-induced endothelial dysfunction and vascular disease.
  • Evidence snippets:
  • Snippet 1 (score: 0.395) > lead to the accumulation of Hcy and its metabolites in the blood-hyperhomocysteinemia (HHcy)-which is an independent risk factor for cardiovascular disease (CVD) and causes endothelial dysfunction, a hallmark of atherosclerosis (Dayal and Lentz 2008). However, molecular mechanisms underlying the pathophysiology of HHcy are not fully understood (Jakubowski 2011(Jakubowski , 2013;;Perla-Kajan et al. 2007). One hypothesis states that metabolic conversion of Hcy to Hcythiolactone initiates a pathway that leads to pathologies associated with HHcy (Jakubowski 1997a(Jakubowski , 1999(Jakubowski , 2007)). Hcy-thiolactone is chemically reactive and modifies ε-amino groups of protein lysine residues, which generates immunogenic and toxic N-homocysteinylated protein (N-Hcy-protein) (Jakubowski 2008(Jakubowski , 2013;;Jakubowski et al. 2000). > In humans and mice, HHcy leads to the accumulation of Hcy-thiolactone and N-Hcy-protein, in addition to Hcy (Chwatko et al. 2007;Jakubowski et al. 2008Jakubowski et al. , 2009)). We and other investigators have shown that HHcy induces changes in gene expression in mouse models that are associated with atherothrombotic disease (Devlin et al. 2005;DiBello et al. 2010;Ingrosso et al. 2003;Kim et al. 2011;Pogribny et al. 2008;Sharma et al. 2006;Suszynska-Zajczyk et al. 2014a, b, c, d). However, it is not known what mechanism(s) are involved and which metabolite-Hcy itself, Hcy-thiolactone, or N-Hcy-protein-is responsible for changes in gene expression. > The key to understanding mechanisms by which HHcy disrupts normal cellular function and ultimately causes disease is to identify genes whose expression is affected by individual Hcy metabolites.

[6] Etiology and Pathophysiology of Hypoparathyroidism: A Narrative Review

  • Authors: J. Pasieka, K. Wentworth, C. Yeo, S. Cremers, D. Dempster et al.
  • Year: 2022
  • Venue: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • URL: https://www.semanticscholar.org/paper/d16b370779057b3b965ce1d52640428c9f80bbea
  • DOI: 10.1002/jbmr.4714
  • PMID: 36153665
  • PMCID: 10364481
  • Citations: 58
  • Influential citations: 5
  • Summary: Given the pervasive nature of PTH deficiency across multiple organ systems, a detailed review of the skeletal, renal, neuromuscular, and ocular complications is provided.
  • Evidence snippets:
  • Snippet 1 (score: 0.391) > Etiology and Pathophysiology of Hypoparathyroidism: A Narrative Review

[7] Computational drug discovery approaches identify mebendazole as a candidate treatment for autosomal dominant polycystic kidney disease

  • Authors: P. Brownjohn, A. Zoufir, Daniel J O’Donovan, Saatviga Sudhahar, A. Syme et al.
  • Year: 2024
  • Venue: Frontiers in Pharmacology
  • URL: https://www.semanticscholar.org/paper/a595e78572ca02b8cb2897bfc4a989a2b021b279
  • DOI: 10.3389/fphar.2024.1397864
  • PMID: 38846086
  • PMCID: 11154008
  • Citations: 3
  • Summary: It is determined that the anthelmintic mebendazole was a potent anti-cystic agent in human cellular and in vivo models of ADPKD, and is likely acting through the inhibition of microtubule polymerisation and protein kinase activity.
  • Evidence snippets:
  • Snippet 1 (score: 0.390) > Targets and molecules were ultimately filtered for validation based on biological and chemical insights, and the potential for clinical translation.Earlier this year, Wilk et al., 2023 applied a similar transcriptomic approach to us, in that case making use of publicly available transcriptomic datasets to create Pkd2-specific ADPKD disease signatures, from which signature reversion was sought from the Library of Integrated Network-based Cellular Signatures (LINCs) drug signature database in order to identify drug repurposing candidates.While one group has previously made use of a knowledge graph-based approach to prioritise preclinically active compounds with the highest chance of clinical translation (Malas et al., 2019), to our knowledge, the current study provides the first combined application of transcriptomic and machine-learning approaches to identify and prioritise putative treatments for ADPKD, and further deconvolute potential mechanisms of action for experimental validation. > In summary we report, using computational, in vitro and in vivo approaches, that the anthelmintic drug mebendazole ameliorates disease-relevant phenotypes in cellular and animal models of ADPKD.We further show that this effect is likely primarily due to the inhibitory effect of mebendazole on the polymerisation of microtubules, which underlie cellular processes important in ADPKD, including cell proliferation, transport, and cilia signalling, and extends previous work linking the importance of the microtubule network to ADPKD pathophysiology.We also describe the inhibitory profile of mebendazole on known and novel protein kinase targets, some of which have previously been implicated in ADPKD, suggesting mebendazole may be acting via polypharmacology to impact disease mechanisms.We acknowledge that further experimental efforts will be required to confirm the actions of mebendazole on these putative targets in relevant disease model systems.It would be particularly informative to investigate these mechanisms in dedicated in vivo studies, where the effects of mebendazole on a wider range of ADPKD-relevant cell types and phenotypes could be evaluated.

[8] Modeling psychiatric disorders: from genomic findings to cellular phenotypes

  • Authors: Anna Falk, Vivi M. Heine, A. Harwood, Patrick F. Sullivan, M. Peitz et al.
  • Year: 2016
  • Venue: Molecular Psychiatry
  • URL: https://www.semanticscholar.org/paper/235b41240d78140de7ab06a3ad8a7d0b1bdff1a5
  • DOI: 10.1038/mp.2016.89
  • PMID: 27240529
  • PMCID: 4995546
  • Citations: 77
  • Influential citations: 2
  • Summary: The challenges for modeling of psychiatric disorders, potential solutions and how iPSC technology can be used to develop an analytical framework for the evaluation and therapeutic manipulation of fundamental disease processes are critically reviewed.
  • Evidence snippets:
  • Snippet 1 (score: 0.386) > The key challenge for iPSC-based disease modeling is to identify one or more relevant cellular phenotypes that accurately represent the disease pathophysiology. Increasing numbers of reports have demonstrated that for many diseases specific pathophysiology can be captured in human iPSC-based disease models. These range from cardiovascular disease, 44,45 cancer, 46,47 ocular disease, 48,49 diabetes mellitus 50,51 and neurological disorders of the brain. 52,53 Can the same approach be applied to complex psychiatric disorders? > The problem is that almost all psychiatric disorders are characterized by clinical signs and symptoms, but lack independent verification from objective biomarkers. Thus, how might these clinical phenotypes manifest themselves in terms of cell behavior? The identity of robust cellular 'readouts', which typify any psychiatric disorder, is a crucial unsolved problem and an area of intense study 54 (Table 2). When satisfactorily answered, this will herald a new degree of biological objectivity and quantification for the study of psychiatric disorders. > The aim is to find a single or small number of cell phenotypes or parameters that strongly associate with psychiatric disorders, and establish a cellular profile characteristic of cells derived from the general patient population. Although a consensus set of cellular phenotypes for psychiatric disorder is yet to be established, we can define some of their desired characteristics. First, cellular phenotypes have to relate to the biological pathways identified by genetics. Second, although there are many risk genes in disparate biological pathways, at some level, phenotypes should converge onto a much smaller grouping. Third, phenotypes need to be quantifiable. Finally, to be useful for drug development cellular phenotypes should be reversed by pharmacological treatment, although not necessarily by drugs in current use. > Although human iPSC-based approaches underrepresent the complexity of the human central nervous system, cellular phenotypes are likely to lie more proximal to molecular disease mechanisms than phenotypes seen at the level of a tissue or organism, 55 and thus may bypass compensatory homeostatic (2) Gene expression profiles of SCZ human iPSC neurons identified altered expression of many components of the cyclic AMP and WNT signaling pathways. > (3

[9] Novel variants in KAT6B spectrum of disorders expand our knowledge of clinical manifestations and molecular mechanisms

  • Authors: M. Yabumoto, Jessica Kianmahd, Meghna Singh, Maria F. Palafox, Angela Wei et al.
  • Year: 2021
  • Venue: Molecular Genetics & Genomic Medicine
  • URL: https://www.semanticscholar.org/paper/3a47a1b1208ba7420900b090d3d7d712ed391719
  • DOI: 10.1002/mgg3.1809
  • PMID: 34519438
  • PMCID: 8580094
  • Citations: 12
  • Influential citations: 2
  • Summary: A range of features previously described for KAT6B‐related syndromes are identified, including concern for keratoconus, sensitivity to light or noise, recurring infections, and fractures in greater numbers than previously reported.
  • Evidence snippets:
  • Snippet 1 (score: 0.386) > Finally, as gene-centric models of disease have started to take hold, understanding the underlying functional mechanisms that are affected can help us elucidate the effect on molecular and cellular phenotypes that are regulated by KAT6B (Klein et al., 2019;Sheikh et al., 2012). We developed a model of KAT6B truncating variants in a human cell line to explore how these variants result in differential regulation of key transcripts. These types of approaches have been performed in a high throughput manner for tumor suppressor genes like BRCA1 (Findlay et al., 2018) and TP53 (Kotler et al., 2018) and can help identify key pathways that are dysregulated by KAT6B-related disorders and could be future targets for translational research. > Here, we analyze 20 clinical cases representing a KAT6B-related clinical spectrum across three domains: their genotype, phenotype, and experience with genetic counseling resources. Furthermore, we developed an in vitro model of KAT6B mutations using CRISPR technology to explore the effect of protein truncation on global transcriptional regulation. Here we demonstrate that the genes that drive core clinical phenotypes are enriched in our in vitro model system. Together, we show that our clinical observations parallel the transcriptional processes in our cell model systems which allow for a further understanding of the mechanisms underlying the KAT6Brelated clinical spectrum.

[10] Investigating the role of NPR1 in dilated cardiomyopathy and its potential as a therapeutic target for glucocorticoid therapy

  • Authors: Yaomeng Huang, Tongxin Li, Shichao Gao, Shuyu Li, Xiaoran Zhu et al.
  • Year: 2023
  • Venue: Frontiers in Pharmacology
  • URL: https://www.semanticscholar.org/paper/be229f6f2059faab4c97ec0a04bd055adab9dfe1
  • DOI: 10.3389/fphar.2023.1290253
  • PMID: 38026943
  • PMCID: 10662320
  • Citations: 4
  • Summary: Natriuretic peptide receptor 1 (NPR1) was identified as a core gene associated with DCM through bioinformatics analysis and led to substantial improvements in cardiac and renal function, accompanied by an upregulation of NPR1 expression.
  • Evidence snippets:
  • Snippet 1 (score: 0.386) > Multiple pathways and molecules are involved in this process; however, the detailed underlying mechanisms remain unclear. In recent years, with the development of high-throughput sequencing and gene chip technologies, the use of bioinformatics technology to explore the occurrence, development, and prognosis of diseases has become a hot topic for scholars worldwide (Hwang et al., 2018;Nayor et al., 2019;Rinschen et al., 2019;Sturm et al., 2019;Montaner et al., 2020). > The present study aimed to use bioinformatics technology to screen for DCM-related genes and investigate their mechanisms, with the purpose of revealing the pathogenesis of DCM and seeking treatment methods. The GSE3586 dataset, containing expression profiles related to DCM, was selected from the Gene Expression Omnibus (GEO) database. This study aimed to predict the core genes that may play crucial roles in disease progression at the molecular level through the enrichment of relevant molecular pathways associated with DCM. Furthermore, the phenotype of the core genes was validated to further support the results of the bioinformatics analysis through basic and clinical experiments. Additionally, the role of glucocorticoids in DCM treatment is discussed in this article with the purpose of providing a theoretical and experimental basis for exploring the pathogenesis of DCM and elucidating therapeutic methods. This study also provides a theoretical reference for the interpretation, early diagnosis, and treatment of DCM.

[11] Cardiomyocytes Derived from Induced Pluripotent Stem Cells as a Disease Model for Propionic Acidemia

  • Authors: Esmeralda Alonso-Barroso, B. Pérez, L. Desviat, E. Richard
  • Year: 2021
  • Venue: International Journal of Molecular Sciences
  • URL: https://www.semanticscholar.org/paper/da649a0f04477c53b448c5ac5f873f8762235290
  • DOI: 10.3390/ijms22031161
  • PMID: 33503868
  • PMCID: 7865492
  • Citations: 16
  • Influential citations: 1
  • Summary: The novel results show that PA iPSC-cardiomyocytes represent a promising model for investigating the pathological mechanisms underlying PA cardiomyopathies, also serving as an ex vivo platform for therapeutic evaluation.
  • Evidence snippets:
  • Snippet 1 (score: 0.385) > The study of the mechanisms involved in disease physiopathology has been mainly performed using the hypomorphic PA mouse model that mimics the biochemical and clinical phenotype [5]. Using this model, bioenergetic failure, oxidative damage and deregulation of miRNAs induced by accumulating propionyl-CoA have been described as potential mechanisms contributing to PA physiopathology [6][7][8]. The limitations of animal models for the study of cardiac energy metabolism [9] and of the commonly available cellular human models such as fibroblasts, underline the importance of generating new relevant cell models to provide deeper insight into the underlying mechanisms of disease. The use of in vitro models with human cellular context is highly recommended and, in this sense, induced pluripotent stem cells (iPSCs) have certain advantages since they provide the genetic background of the patient and represent an unlimited source of biological material for the study of pathophysiology and treatment effectiveness [10]. We have previously generated an iPSC line from a PA patient with defects in the PCCA gene that showed full pluripotency, differentiation capacity and genetic stability [11]. > In the present study, we aimed to establish a platform that served as a disease model to study the cellular and molecular alterations operating in cardiac tissue affected by PA disease. We described the characterization of cardiomyocytes derived from the PCCA iPSC line (PCCA iPSC-CMs) and the analysis of specific pathways potentially involved in cardiac PA physiopathology.

[12] Rare Monogenic Diseases: Molecular Pathophysiology and Novel Therapies

  • Authors: I. Condò
  • Year: 2022
  • Venue: International Journal of Molecular Sciences
  • URL: https://www.semanticscholar.org/paper/6aece75e6947f102b657851b74e8b96df5e654c1
  • DOI: 10.3390/ijms23126525
  • PMID: 35742964
  • PMCID: 9223693
  • Citations: 18
  • Influential citations: 2
  • Summary: A rare disease is defined by its low prevalence in the general population and its presence in a very small number of people.
  • Evidence snippets:
  • Snippet 1 (score: 0.381) > The selective expression or the particular role of specific genes in a single tissue explains the appearance of organ-specific inherited diseases. This is the case of genetic disorders of the kidney, which include dominant and recessive forms of cystic diseases, and renal tubulopathies. Mutations in polycystin-1 (PKD1) or -2 (PKD2) genes lead to autosomaldominant polycystic kidney disease (ADPKD), whose gender-dependent phenotype was analyzed in the study by Talbi et al. [9]. These results, obtained in mice lacking PKD1 expression, show the involvement of intracellular Ca2+ levels in the more severe phenotype affecting male ADPKD animals. Altogether, identification of the molecular mechanisms underlying enhanced Ca2+ signaling and proliferation in cells from male kidneys may contribute to develop novel therapeutics for ADPKD [9]. The autosomal-recessive form of polycystic kidney disease (ARPKD) mostly arises from defects in the gene named polycystic kidney and hepatic disease 1 (PKHD1), whereas a minority of cases is linked to a second causative gene DZIP1L. To examine the still unclear molecular pathophysiology of ARPKD, Cordido et al. recapitulate known molecular disease mechanisms and possible therapeutic approaches, from cellular and animal models to clinical trials [10]. The knowledge of ARPKD pathogenic pathways, involving the epidermal growth factor receptor (EGFR) axis, the production of adenylyl cyclase adenosine 3 ,5 -cyclic monophosphate (cAMP) and the activation of several protein kinases, begins to stimulate possible pharmacological interventions [10]. Inherited loss of function in various electrolyte transport proteins located along the nephron leads to two types of kidney tubulopathy with overlapping clinical symptoms: Gitelman and Bartter syndromes. The review by Nuñez-Gonzalez et al. aims to explain the different molecular basis of these difficult to diagnose monogenic syndromes. Moreover, the authors provide an overview of current therapeutic approaches and highlight the presence of common and specific options for Gitelman and Bartter patients [11].

[13] Transcriptional profiling of Hutchinson-Gilford progeria patients identifies primary target pathways of progerin

  • Authors: Sandra Vidak, Sohyoung Kim, Tom Misteli
  • Year: 2026
  • Venue: Nucleus
  • URL: https://www.semanticscholar.org/paper/4bd99b0875508364d8672b6da5a50d024d485a53
  • DOI: 10.1080/19491034.2025.2611484
  • PMID: 41489464
  • PMCID: 12773485
  • Summary: To probe the clinical relevance of previously implicated cellular pathways and to address the extent of gene expression heterogeneity between patients, transcriptomic analysis of a comprehensive set of HGPS patients finds misexpression of several cellular pathways, including multiple signaling pathways, the UPR and mesodermal cell fate specification.
  • Evidence snippets:
  • Snippet 1 (score: 0.381) > Oxidative stress represents another key pathogenic mechanism in HGPS, as impaired NRF2 activity or increased reactive oxygen species (ROS) levels are sufficient to recapitulate HGPSassociated phenotypes [17,32,60]. Collectively, these findings underscore the multifactorial nature of HGPS pathogenesis, implicating interconnected signaling cascades involved in inflammation, oxidative stress, proteostasis, and vascular remodeling. Reassuringly, our findings indicate that many of the major pathways that have been described to contribute to HGPS phenotypes in mouse and cellular disease models are also misregulated in progeria patients, and targeting these pathways may provide therapeutic avenues to mitigate disease severity and improve outcomes in HGPS. > Although individuals with HGPS typically exhibit a characteristic set of clinical features, such as craniofacial abnormalities, growth retardation, and cardiovascular complications, there is notable variability in the age of onset, severity, and progression of symptoms between patients [7,9]. At the cellular level, HGPS is associated with several hallmark abnormalities, including nuclear envelope defects, decreased expression of several nuclear proteins and epigenetic marks, mitochondrial dysfunction, and increased cellular senescence [1,11,30,31,61]. These cellular phenotypes also exhibit considerable variation between patients, possibly contributing to differences in clinical outcomes. Our results indicate that even though some degree of transcriptional heterogeneity between the individual patients exists, the majority of patients exhibit misregulation of a set of shared pathways, suggesting that these pathways are universal driver mechanisms in HGPS. Further work is needed to understand the molecular and genetic factors that underlie inter-individual variability in disease expression and progression. > A limitation of pathway analysis of HGPS patient samples is to distinguish the pathways which are directly targeted by the disease-causing progerin protein and the emergence of adaptive secondary response pathways during progression of the disease in patients during their lifetime. The same caveat applies to the use of cell-based models used in the study of HGPS disease mechanisms.

[14] Pseudopseudohypoparathyroidism: an unusual case

  • Authors: S. Munigoti
  • Year: 2018
  • Venue: Journal of Clinical and Scientific Research
  • URL: https://www.semanticscholar.org/paper/0e9c1005b0ab7e8721eb0f2bd430c4bac267db24
  • DOI: 10.4103/JCSR.JCSR_43_18
  • Summary: An unusual case of a 22-year-old male patient who presented with phenotypic features of Albright's hereditary osteodystrophy, but had associated multiple hormonal deficiencies suggestive of pseudo-pseudohypararthyroidism.
  • Evidence snippets:
  • Snippet 1 (score: 0.380) > Pseudopseudohypoparathyroidism: an unusual case

[15] Targeting Hepatic Stellate Cells for the Prevention and Treatment of Liver Cirrhosis and Hepatocellular Carcinoma: Strategies and Clinical Translation

  • Authors: Hao Xiong, Jinsheng Guo
  • Year: 2025
  • Venue: Pharmaceuticals
  • URL: https://www.semanticscholar.org/paper/76e92127053136900f7e3f10e2c9278251ced5d2
  • DOI: 10.3390/ph18040507
  • PMID: 40283943
  • PMCID: 12030350
  • Citations: 10
  • Summary: HSC-targeted approaches using specific surface markers and receptors may enable the selective delivery of drugs, oligonucleotides, and therapeutic peptides that exert optimized anti-fibrotic and anti-HCC effects.
  • Evidence snippets:
  • Snippet 1 (score: 0.375) > Significant progress has been made in elucidating the cellular and molecular mechanisms of liver fibrosis; however, only a few findings have been successfully translated into clinical applications. Firstly, the high cost of drug development and target validation necessitates prolonged timelines and substantial financial investment. Secondly, as regulatory requirements become more stringent, there is an increasing demand for drugs with well-defined clinical efficacy and safety profiles. Moreover, the efficacy observed in animal models often fails to fully translate to clinical settings due to differences in pharmacokinetics, extracellular matrix (ECM) cross-linking, and disease pathophysiology. Despite advancements in anti-fibrotic drug development, accurately identifying ideal noninvasive biomarkers for fibrotic activity and establishing consensus on optimal clinical endpoints remain significant challenges [113,114]. > Currently, addressing the underlying cause remains the only proven strategy to halt or reverse liver fibrosis progression, while the development of effective anti-fibrotic therapies continues to pose a major challenge in liver disease management. Over the past few decades, substantial progress has been made in elucidating the cellular and molecular mechanisms underlying liver fibrosis. Liver fibrosis is a complex pathological change involving multiple cells, factors, and pathways, and the study of the cellular and molecular mechanisms of its occurrence and development provides an important theoretical basis and therapeutic target for clinical drug development. It is anticipated that improved animal models and well-designed clinical trials will facilitate the successful translation of anti-fibrotic research into effective clinical treatments in the near future.

[16] Direct Sarcomere Modulators Are Promising New Treatments for Cardiomyopathies

  • Authors: O. Tsukamoto
  • Year: 2019
  • Venue: International Journal of Molecular Sciences
  • URL: https://www.semanticscholar.org/paper/07467943fe92ce135b52ded5e5dea2bfc2ddf179
  • DOI: 10.3390/ijms21010226
  • PMID: 31905684
  • PMCID: 6982115
  • Citations: 16
  • Summary: The direct inhibition of sarcomere contractility may be able to suppress the development and progression of HCM with hypercontractile mutations and improve clinical parameters in patients with HCM, and direct activation of sar COMs modulators that can positively influence the natural history of cardiomyopathies represent promising treatment options.
  • Evidence snippets:
  • Snippet 1 (score: 0.374) > Hereditary DCM can be caused by single point mutations in sarcomere proteins. However, the link between point mutations and clinical phenotypes in DCM is not thoroughly understood in most cases. Recent advances in biochemical, biophysical, stem cell, and gene editing technologies have provided a better understanding of the molecular mechanisms through which the initial insult in DCM (i.e., mutations in a sarcomere protein) induces alterations in cellular organization and contractility, resulting in disease phenotypes. In particular, hiPSC-CMs and genetically modified animals are excellent models because they can capture the initial molecular phenotype that occurs before major compensatory mechanisms mask it.

[17] Aberrant NLRP3 Inflammasome Activation Ignites the Fire of Inflammation in Neuromuscular Diseases

  • Authors: Christine Péladeau, J. Sandhu
  • Year: 2021
  • Venue: International Journal of Molecular Sciences
  • URL: https://www.semanticscholar.org/paper/763a36db080236fca8cde89b2afcdf056f3584d0
  • DOI: 10.3390/ijms22116068
  • PMID: 34199845
  • PMCID: 8200055
  • Citations: 18
  • Influential citations: 1
  • Summary: Whether therapeutic targeting of the NLRP3 inflammasome components is a viable approach to alleviating the detrimental phenotype of neuromuscular diseases and improving clinical outcomes is examined.
  • Evidence snippets:
  • Snippet 1 (score: 0.374) > Despite a large number of mechanisms that have been identified in muscle degeneration and nerve cell loss, none have proven to be the primary cause of the disease. There is much need for a deeper understanding of the biology of the pathogeneses and the molecular mechanisms that are activated early in the diseases in order to identify "druggable" targets and disease-modifying treatments for these devastating diseases. > Human iPSC technologies are emerging as useful platforms for disease modeling to study pathogenic mechanisms and discover novel therapeutics for neuromuscular diseases [211,237]. Indeed, patient-derived iPSCs are being used to create a "patient-in-adish" disease model to derive relevant cell types for testing potential therapeutics, paving the way towards personalized medicine. This approach allows drug screening in a dish prior to administration to patients and "bench-to-bedside" translation of potential therapies. Additionally, iPSCs may also be used to stratify patients with various phenotypes and guide future clinical trials for bringing improved therapies to patients. Since multiple cell types are involved in disease pathogenesis, future research efforts need to be focused on deciphering "disease-specific signatures" at single-cell resolution, and not only in neuronal cells but also in non-neuronal cells. The application of modern technologies, including single-cell RNA sequencing and spatial transcriptomics, to neuromuscular diseases, will allow to ascertain cellular vulnerability and cell-specific mechanisms during various stages of disease progression. > The vital roles of the NLRP3 inflammasome in neuromuscular diseases such as DMD, LGMD and ALS, reveal that targeting this pathway is indeed a promising therapeutic strategy. Dysregulation of the NLRP3 inflammasome in muscle tissues by muscle damage, membrane instability, extracellular ATP and Ca 2+ ions or signals from infiltrating immune cells, clearly impacts the progression of neuromuscular and neurodegenerative disorders. Thus, modulation of these pathways involved with activation and assembly of NLRP3 inflammasome could be truly beneficial.

[18] Clinical metabolomics in type 2 diabetes mellitus: from pathogenesis to biomarkers

  • Authors: Chuanxin Liu, Hetao Chen, Yujin Ma, Lei Zhang, Lulu Chen et al.
  • Year: 2025
  • Venue: Frontiers in Endocrinology
  • URL: https://www.semanticscholar.org/paper/36f8d26a208b7b96763df2e9aa3211e440031c0e
  • DOI: 10.3389/fendo.2025.1501305
  • PMID: 40070584
  • PMCID: 11893406
  • Citations: 11
  • Summary: The results facilitate understanding the pathophysiology and mechanism of type 2 diabetes mellitus and supports research in accurate diagnosis, risk prediction, curative effect, distinct stages, and prognosis judgment of T2DM.
  • Evidence snippets:
  • Snippet 1 (score: 0.373) > The metabolome is sensitive to a variety of genetic and environmental stimuli and susceptible to genetic, environmental, and gut microbiome pressures, so subtle differences between individuals can lead to large perturbations in metabolite concentrations and fluxes (15, 24). At present, cystatin C has become an ideal endogenous marker for evaluating glomerular filtration function because it is not affected by sex, age or muscle mass (25). In addition, more and more evidence shows that serum CysC is involved in the pathological process of vascular remodeling and neovascularization, which is closely related to the occurrence and development of diabetic microangiopathy (26). > Eighty-four papers were included in this review and obtained through database searches, namely, PubMed, Cochrane Library, China national knowledge internet(CNKI), General Purpose, and VIP Database. The keywords for the searches were "metabolomics" and "type 2 diabetes mellitus" and its complications. The papers were incorporated by reading and summarizing the literature according to the classification standards (27). The profound analysis of clinical differential metabolites identified in type 2 diabetes and its complications were conducted concerning composition, frequency of category, sample type, and pathways to explore the pathological mechanism of type 2 diabetes and its complications to provide a systematic basis for clinical diagnosis, risk stratification, comprehending disease progression, prognosis assessment, and drug efficacy. Our goal is to apply metabolomics to clinical diagnostic biomarkers, metabolic mechanisms, and prognostic observations, and early diagnosis can be made through metabolites to avoid progression to more serious complications.

[19] A Lifelike guided journey through the pathophysiology of pulmonary hypertension—from measured metabolites to the mechanism of action of drugs

  • Authors: Nathan Weinstein, Jørn Carlsen, S. Schulz, T. Stapleton, Hanne H. Henriksen et al.
  • Year: 2023
  • Venue: Frontiers in Cardiovascular Medicine
  • URL: https://www.semanticscholar.org/paper/0b2dc837dea11add7e2f67f06acf6280ac96a019
  • DOI: 10.1101/2023.11.21.23298782
  • PMID: 38845688
  • PMCID: 11153715
  • Citations: 4
  • Summary: The present study shows the power of mining knowledge graphs using Lifelike's diverse set of data analytics functionalities for developing knowledge-driven hypotheses on PH pathophysiological and drug mechanisms and their interactions.
  • Evidence snippets:
  • Snippet 1 (score: 0.372) > Despite substantial progress in the understanding of PH pathophysiology over the last years, the detailed mechanisms underlying PH remain elusive due to the complex interplay of dysregulated biological processes.Also, although the mechanisms of action of some drugs that have been successfully used for the treatment of PH have been proposed, certain drugs may show additional mechanisms of action that are yet to be identified.Understanding these additional mechanisms of action is crucial for the personalized and thus more effective treatment of PH patients.In this study, we aimed to generate detailed mechanistic hypotheses of pathophysiological processes in PH using our in-house developed software platform Lifelike.Importantly, we have focused our analyses on the potential effects of blood plasma metabolites from PH patients on pulmonary endothelial and smooth muscle cells.Moreover, we used Lifelike to investigate the mechanisms of action of existing and new drugs used for the treatment of PH in more detail.We have achieved this by analyzing metabolite data and receptor ligands on the curated database Reactome using graph algorithms, and by combining our software's additional data analytics functionalities, including statistical enrichment and semantic analysis of textual information from Lifelike's knowledge graph.Additionally, we validated, interpreted, and extended our results based on relevant existing literature.This entire process allowed us to explore the pathophysiology of PH and to propose the model shown in figure 3 and summarized in figure 6.Further, Lifelike allowed us to generate the hypotheses discussed in the following sections and shown in Tables 2 and 3. > Lifelike also enables the reader of a biology article to quickly find the molecules, diseases, and phenotypes that are discussed in the manuscript or included in the figures through entity recognition.For instance, genes detected in articles by Lifelike's entity recognition system can be used to create an enrichment table where the genes can be associated with biological processes, molecular functions, and cell structures by GO enrichment.This allows the reader to find context-specific information quickly, and to extend the knowledge beyond what is described in the article with other sources of information (Table 1 row 21) We encourage the reader to upload this manuscript in PDF format into Lifelike for improved reading and knowledge extraction capabilities.

[20] Mitochondrial Dysfunction in Diabetes: Shedding Light on a Widespread Oversight

  • Authors: F. Iheagwam, A. J. Joseph, E. D. Adedoyin, Olawumi Toyin Iheagwam, Samuel Akpoyowvare Ejoh
  • Year: 2025
  • Venue: Pathophysiology
  • URL: https://www.semanticscholar.org/paper/dbf8042761c1a5fc50f8cd894cc498505abac7cb
  • DOI: 10.3390/pathophysiology32010009
  • PMID: 39982365
  • PMCID: 12077258
  • Citations: 30
  • Summary: This review aims to elucidate the complex link between mitochondrial dysfunction and diabetes, covering the spectrum of diabetes types, the role of mitochondria in insulin resistance, highlighting pathophysiological mechanisms, mitochondrial DNA damage, and altered mitochondrial biogenesis and dynamics.
  • Evidence snippets:
  • Snippet 1 (score: 0.371) > The landscape of DM research is continuously evolving, with emerging technologies and approaches offering new insights into the pathophysiology of the disease and potential therapeutic targets. Advancements in omics technologies, encompassing genomes, transcriptomics, proteomics, and metabolomics, have transformed the molecular mechanisms underlying DM [134]. High-throughput sequencing techniques enable comprehensive analysis of genetic variants, gene expression profiles, protein abundance, and metabolite levels associated with DM and its complications [135]. Single-cell omics approaches provide unprecedented resolution and granularity, allowing researchers to dissect cellular heterogeneity and identify novel cell types, subpopulations, and signalling pathways involved in DM pathogenesis. Integrating multi-omics data sets offers a systems-level perspective of DM, unravelling complex networks of molecular interactions and regulatory circuits underlying disease progression [136]. > In addition to omics technologies, advances in imaging modalities, such as MRI, PET, and optical imaging, enable non-invasive visualisation and quantification of metabolic, functional, and structural changes. Molecular imaging probes targeting specific biomarkers and metabolic pathways provide valuable insights into disease mechanisms and treatment responses in preclinical and clinical settings [85]. Despite significant progress in DM research, numerous unanswered questions and knowledge gaps persist, hindering the ability to develop effective prevention and treatment strategies. Key areas requiring further investigation include the role of epigenetics, environmental factors, and the microbiome in DM susceptibility and progression. Moreover, the interaction between environmental cues and genetic predisposition remains incompletely understood, highlighting the need for comprehensive multi-omics studies and large-scale epidemiological analyses to identify gene-environment interactions and modifiable risk factors for DM [137]. Furthermore, the heterogeneity of DM phenotypes and clinical outcomes poses a challenge for personalised medicine approaches, necessitating robust biomarkers and predictive models to stratify patients based on disease subtypes, prognosis, and treatment response [138].

Notes

  • This provider combines search_papers_by_relevance with snippet_search.
  • No synthesis or second-stage model call is performed.